

A key goal has been to facilitate the career development of the next generation of endocrinologists. My research career has primarily focused on understanding why estrogens are associated with the development of breast cancer and on the hormonal regulation of established tumors. Under my leadership, a multi-disciplinary team has spent more than two decades developing first, second and third generation aromatase inhibitors for breast cancer and comparing the relative efficacy of these agents with the anti-estrogen, tamoxifen. These studies required a keen understanding of methodology for measurements of low levels of estrogen in plasma of postmenopausal women. With validation of the use of the third generation aromatase inhibitors for therapy in women, our attention turned to developing a greater understanding of the molecular mechanisms of *de novo* and *acquired resistance* to hormone therapy. As the PD of a program project grant, my group and I developed a unique model to determine the adaptive processes that resulted in resistance, a model called long term estradiol deprived (LTED) cells. To fully understand this model, we utilized a panoply of techniques and ultimately established key roles for MAP kinase, PI-3-kinase, and mTOR in this process. Adaptation resulted in enhanced sensitivity to both the proliferative and pro-apoptotic effects of estradiol. As aromatase inhibitors block estrogen biosynthesis, we initiated studies to test the hypothesis that estrogen metabolites contribute to the induction of breast cancer in estrogen receptor (ER) knock-out mice. We demonstrated that both ER-dependent and -independent mechanisms are involved in the carcinogenic process. These studies led us to believe that breast cancer prevention would be the next logical step in use of aromatase inhibitors. Effective preventative strategies depend upon an understanding of the pathogenesis and kinetics of breast cancer growth. Emerging concepts led to the study of TSECs (tissue selective estrogen complexes) as a possible means of preventing breast cancer and at the same time treating menopausal symptoms. My present goals are to establish a program whereby retired endocrinologists can re-enter practice and assist in the management of patients with diabetes living in rural, financially challenged, and underserved areas. With six years of experience with more than 350 patients, my published work has demonstrated the feasibility and effectiveness of this approach.,

Key accomplishments:

Objective assessment of research productivity

- *H-score 94
- *Citations 29,600
- *I10 index 308

Publications reporting major contributions.

- *Correlation of lipid values with diabetes –publication of work performed medical residency (ref # 9 cited 255 times)
- *Development of computer based program for analysis of pulsatile LH secretion: said to be the initiating factor for further studies in this field (ref # 12 cited 817 times)
- *Development of 1st, 2nd and 3rd generation aromatase inhibitors for treatment of breast cancer (refs 16, 35, 36, 37, 38, 45, 55, 59, 62, 65, 66, 67, 121, 127, 129, 155, 174, 176, 178, 181, 188, 195, 196, 220)

*First study to demonstrate the efficacy and suppression of testosterone to castrate levels of GnRH agonists for treatment of prostate cancer (ref 101 cited 76 times)

*Demonstrated role of aromatase in the regulation of LH in men (ref 21 cited 246 times)

*Introduced the concept of estrogen deprivation of breast cancer cells which cause estradiol to induce apoptosis and which may explain reduction of breast cancer with conjugated equine estrogen in the Women's Health Initiative study (ref 209 cited 241 times)

*Provided proof of ER mediated and ER independent , direct genotoxic effects of estradiol to cause breast cancer in pre-clinical knock-out mice studies (ref 338, 278, 309 cited 48 times, 264, 89 times)

*Demonstrated the role of membrane ER actions in the growth of breast cancer cells involving SHC, IGF-1 and mTOR (ref 286 cited 357 times)

*Demonstrated the role of estrogen to stimulate breast cancer cell migration and invasion (ref 342 cited 48 times)

Publication of Guidelines and Scientific Statements

*First author of an ES scientific statement of the effects of menopausal hormone therapy in women (cited 517 times)

*Senior author on ES Guidelines on treatment of menopausal women (cited 108 times)

*First author of a review on treatment of menopausal symptoms in survivors of breast (JCEM in press)

*First author on an analysis of writing the specific aims section of NIH grants (JES in press)

Contributions to Professional Endocrine Societies

*Spearheaded the writing of a long term financial plan for the Endocrine Society when chair of finance committee

*Initiated the International Scholars program of the Endocrine Society

*President of the Endocrine Society 2014

*spearheaded initiatives to support the Next Generation of Endocrinologists when president

* Multiple task force and committee memberships for the Endocrine Society and for the World Health Organization committee on reproduction

* Membership on Council of the International Society of Endocrinology

*Organized first International Aromatase conference (1981) which was followed by 12 other meetings over the next 25 years

*Member of the Endocrine Certification Test writing group for the American Board of Internal Medicine

Major Research Funding

*Continuously funded by the NIH for 40+ years (list provided on request)

International Lectures

*Speaker in more than 25 countries on various topics in endocrinology

Academic Awards:

| | |
|-----------|---|
| 1964-65 | Deans Award, University of Michigan Medical School |
| 1969 | Resident Achievement Award, University of Michigan Hospital |
| 1970 | Diplomate American Board of Internal Medicine |
| 1972-74 | Special Research Fellowship Award No. FO3-HD52461, National Institutes of Health and Human Development |
| 1975 | Fellowship of American College of Physicians |
| 1976 | Subspecialty in Endocrinology, American Board of Internal Medicine |
| 1978-79 | Fogarty Senior International Fellowship Award F06 TW 00150, NIH |
| 1982 | Faculty Scholar Award, The Pennsylvania State University |
| 1992 | Ciba-Geigy - ANT International Award, Eubiosia Prize |
| 1993 | Susan G. Komen Foundation - Brinker International Award for Breast Cancer Clinical Research |
| 2005 | CLAS Distinguished Scientist Award |
| 2006 | Robert H. Williams Distinguished Leadership Award, The Endocrine Society |
| 2006 | The William McGuire Memorial Lectureship, the San Antonio Breast Cancer Symposium |
| 2012 | Sanctae Crucis Award, College of the Holy Cross |
| 2012 | Member - Mount Nittany Society, Pennsylvania State University |
| 2013 | Selected as a Top Endocrinologist in Charlottesville, VA by the International Association of Healthcare Professionals |
| 2014 | Selected as one of America's Top Physicians by Consumers Research Council of America |
| 2015 | Selected for inclusion in the Best Doctors in America 2015-2016 database |
| 2015 | Selected as a Top Endocrinologist in Charlottesville, VA by the International Association of HealthCare Professionals (IAHCP) |
| 2017-2019 | Best Doctors |
| 2020 | Koch Lifetime Achievement Award of the Endocrine Society |

Scientific Societies:

Society for the Study of Reproduction
American Federation of Clinical Research
The Endocrine Society
Fellowship in the American College of Physicians
American Clinical and Climatological Association
American Society of Andrology
American Society of Breast Diseases
American Society of Clinical Investigation
Association of American Physicians
American Society of Clinical Oncology
Vice-President, The Pennsylvania Endocrine Society, 1985-88
President, The Pennsylvania Endocrine Society, 1988-91
Association of Professors of Medicine, 1993-1995
Wayne County Medical Society, 1993-1995

Medical School Activities:

Pennsylvania State University School of Medicine

1972 Member, Problem Solving Committee
1973, 1981 Chairman, Human Use of Radioisotopes Subcommittee
1973 Radiation Safety Committee
1974 Member, Medical Audit Committee
1975-76 Member, Penn State Graduate Council
1975-88 Member, Specialized Cancer Research Center
1975-83 Member, Specialized Cancer Research Center Development Committee
1976-78 Member, Chemical Safety Committee
1976-77 Counselor, Faculty Organization
1980-83 Clinical Investigation Committee
1983-88 Cancer Research Center Advisory Committee
1986-87 Chairman, Sabbatical Leave Committee
1987-93 Sabbatical Leave Committee
1992-93 Chairman, Clinical Research Center Advisory Committee
1992-93 Member, Women's Health Task Force Committee
University of Virginia School of Medicine
1996-2000 Promotion and Tenure Committee

Professional Activities:

1979-82 Editorial Board, Journal of Clinical Endocrinology and Metabolism
1980-98 Editorial Board, Breast Cancer Research and Treatment
1981 Co-Organizer, International Aromatase Conference - New Perspectives for Breast Cancer, Key Biscayne, FL
1984 Editorial Board, Journal of Enzyme Inhibition
1986-88 Clinical Cancer Program Project Review Committee, NIH-NCI
1987 Co-Organizer, International Conference on Aromatase, Miami, FL
1987-89 Council Member, American Society of Andrology
1987 Member, External Review Committee, World Health Organization Task

| | |
|-----------|---|
| 1987-90 | Force for Development of Male Contraceptives Prostate Cancer Working Group of the Organ Systems Coordinating Center, National Cancer Institute |
| 1988 | Chairman, Postgraduate Course, Amer. Society of Andrology, Houston, TX |
| 1989-91 | VA Merit Review Board for Endocrinology |
| 1996-99 | Chairman, Finance Committee of the Endocrine Society |
| 1998- | Editorial Board, the journal <i>Women and Cancer</i> |
| 1999- | Editorial Board, the journal <i>Steroids</i> |
| 1999- | Member, Women's Health Council of the Hormone Foundation |
| 2000 | Co-Chair, International Organizing Committee of the International Conference "Hormonal Carcinogenesis: Mechanisms and Prevention" |
| 2001-2005 | Member, American Board of Internal Medicine Subspecialty Board on Endocrinology, Diabetes, and Metabolism |
| 2002- | Council member, Endocrine Society |
| 2002- | Member, Endocrine Society International Task Force Committee |
| 2002- | Member, American Association of Physicians |
| 2005 | Member Executive Committee, International Society of Endocrinology |
| 2006- | Associate Editor <i>Breast Cancer Research</i> |
| 2006 | Brinker Award for Scientific Distinction 2006 Nomination Committee |
| 2007 | Editorial Board, Polish Journal of Endocrinology Ad Hoc Reviews: <i>Journal of Clinical Investigation</i> , <i>Clinical Endocrinology</i> , <i>Science</i> , <i>Endocrinology</i> , Medical Research Council, Canada, Veterans Administration Merit Review, <i>Metabolism</i> , <i>European Journal of Cancer and Oncology</i> , <i>Annals of Internal Medicine</i> , <i>American Journal of Physiology</i> , Endocrine Section, <i>Psychoneuroendocrinology</i> |

Local, national, and international presentations – provided upon request

1. Lectures delivered in 25 counties (list provided upon request)
2. Lectures delivered at 35 medical schools in the United States (list provided upon request)
3. John Leonard Memorial Lecture at the University of Washington
4. Brinker International Award Lecture
5. CLAS distinguished Scientist Lectureship
6. McGuire Memorial Lectureship
7. Dean's Lectureship at the Pennsylvania State University
8. Plenary lecture at the Endocrine Society
9. Numerous other lectures at National and International Meetings

Peer Reviewed Publications

1. Santen, R.J., Agranoff, B.W. Studies on the estimation of deoxyribonucleic acid and ribonucleic acid in rat brain. Biochem. Biophys Acta 72:251-262, 1963.
2. Davis, G.A., Santen, R.J., Agranoff, B.W. The production of a linear density gradient by means of a proportioning pump. Anal. Biochem. 11:153-154, 1965.
3. Santen, R.J. Automated estimation of diploid and tetraploid nuclei with an electronic particle counter. Exp. Cell Res. 40:413-420, 1965.

4. Santen, R.J., Wright, I.S. Systemic lupus erythematosus associated with pulmonary nocardiosis. Arch. Int. Med. 119:202-205, 1967.
5. Santen, R.J., de Kretser, D.M., Paulsen, C.A., Vorhees, J. Gonadotrophins and testosterone in the XYY syndrome. Lancet 2:371, 1970.
6. Ensink, J.W., Stoll, R.W., Gale, C.C., Santen, R.J., Touber, J.L., Williams, R.H. Effect of aminophylline on the secretion of insulin, glucagon, luteinizing hormone and growth hormone in humans. J. Clin. Endocrinol. Metab. 31:153-161, 1970.
7. Swanson, S.L., Santen, R.J., Smith, D.W. Multiple lentiginos syndrome: New findings of hypogonadotrophism, hyposmia, and unilateral renal agenesis. J. Ped. 78:1037-1039, 1971.
8. Santen, R.J., Leonard, J.M., Sherins, R.J., Gandy, H.M., Paulsen, C.A. Short- and long-term effects of clomiphene citrate on the pituitary-testicular axis. J. Clin. Endocrinol. Metab. 33:970-979, 1971.
9. Santen, R.J., Willis III, P.W., Fajans, S.S. Atherosclerosis in diabetes mellitus: Correlations with serum lipid levels, adiposity, and serum insulin level. Arch. Int. Med. 130:833-843, 1972.
10. Santen, R.J., Paulsen, C.A. Hypogonadotrophic eunuchoidism II. Gonadal responsiveness to exogenous gonadotropins. J. Clin. Endocrinol. Metab. 36:55-63, 1973.
11. Santen, R.J., Paulsen, C.A. Hypogonadotropic eunuchoidism I. Clinical study of the mode of inheritance. J. Clin. Endocrinol. Metab. 36:47-53, 1973.
12. Santen, R.J., Bardin, C.W. Episodic luteinizing hormone secretion in man: Pulse analysis, clinical interpretation, physiologic mechanisms. J. Clin. Invest. 52:2617-2628, 1973.
13. Paulsen, C.A., Santen, R.J. Short and long term therapy with HMG in hypogonadotropic eunuchoid women. IN: Intl. Cong. Series 266: Gonadotropin Therapy in Female Infertility, Excerpta Medica, Amsterdam, pp. 129-136, 1973.
14. Lipton, A., Santen, R.J. Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33:503-512, 1974.
15. Santen, R.J. How narcotics addiction affects reproductive function in women. Contemporary OB/GYN 3:93-96, 1974.
16. Santen, R.J., Lipton, A., Kendall, J. Successful medical adrenalectomy with aminoglutethimide: Role of altered drug metabolism. JAMA 230:1661-1665, 1974.
17. Santen, R.J., Sofsky, J., Bilic, N., Lippert, R. Mechanism of action of narcotics in the production of menstrual dysfunction in women. Fertil. Steril. 26:538-548, 1975.
18. Baker, H.W.G., Santen, R.J., Burger, H.G., de Kretser, D.M., Hudson, B., Pepperell, R.J., Bardin, C.W. Rhythms in the secretion of gonadotropins and gonadal steroids. J. Steroid Biochem. 6:793-801, 1975.
19. Login, I., Santen, R.J. Empty sella syndrome: Sequela of the spontaneous remission of

acromegaly. Arch. Int. Med. 135:1519-1521, 1975.

20. Kulin, H.E., Bell, P.M., Santen, R.J., Ferber, A.J. Integration of pulsatile gonadotropin secretion by timed urinary measurements: An accurate and sensitive 3-hour test. J. Clin. Endocrinol. Metab. 40:783-789, 1975.

21. Santen, R.J. Is aromatization of testosterone to estradiol required for inhibition of LH secretion in men. J. Clin. Invest. 56:1555-1563, 1975.

22. Rolland, R., Santen, R.J., Herman, S.P., Northrup, B. Mechanism of suppression of gonadotropin levels in a patient with a prolactin-secreting adenoma: A longitudinal case study. Am. J. Obstet. Gynecol. 8:1152-1153, 1976.

23. Sanford, E.J., Drago, J. R., Rohner, T.J., Santen, R.J., Lipton, A. AG medical adrenalectomy for advanced prostatic carcinoma. J. Urol. 115:170-174, 1976.

24. Friend, J.N., Judge, D.M., Sherman, B.M., Santen, R.J. FSH-secreting pituitary adenomas: Stimulation and suppression studies in two patients. J. Clin. Endocrinol. Metab. 43:650-657, 1976.

25. Drago, J.R., Rohner, Jr., T.J., Sanford, E.J., Santen, R.J. Diagnosis of hyperparathyroidism. Urology 7:4-6, 1976.

26. Loriaux, D.L., Menard, R., Taylor, R., Pita, J.C., Santen, R.J. Spironolactone and endocrine dysfunction. Ann. Int. Med. 85:630-636, 1976.

27. Santen, R.J., Kulin, H.E., Loriaux, D.L., Friend, J. Spironolactone stimulation of gonadotropin secretion in boys with delayed adolescence. J. Clin. Endocrinol. Metab. 43:1386-1390, 1976.

28. Bixler, E.O., Kales, A., Santen, R.J., Vela-Bueno, A., Soldatos, C.R., Kotas, D.M. Effects of flurazepam (Dalmane) on anterior pituitary secretion. Research Communications in Chemical Pathology in Pharmacology 14:421-429, 1976.

29. Wells, Jr., S.A., Haagensen, D.E., Misbin, R., Lipton, A., Smart, E., Santen, R.J. Studies in patients with metastatic breast carcinoma treated with aminoglutethimide for medical adrenalectomy. Surg. Forum 27:101-102, 1976.

30. Baker, H.W.G., Sonstein, F.M., Eichner, G.J., Santen, R.J., Jefferson, L.S., Bardin, C.W. Perfusion of rat testes and accessory sex organs: A new method. Endocrinology 100:699-708, 1977.

31. Baker, H.W.G., Bailey, D.J., Feil, P.D., Jefferson, L.S., Santen, R.J., Bardin, C.W. Nuclear accumulation of androgens in perfused rat accessory sex organs and testes. Endocrinology 100:709-721, 1977.

32. Santner, S.J., Kulin, H.E., Santen, R.J. Usefulness of urinary gonadotropin measurements to assess luteinizing hormone releasing factor (LRF) responsiveness in hypogonadotropic states. J. Clin. Endocrinol. Metab. 44:313-321, 1977.

33. Judge, D.M., Kulin, H.E., Page, R., Santen, R.J., Trapukdi, S. Hypothalamic hamartoma: A

- source of luteinizing-hormone-releasing factor in precocious puberty. New Engl. J. Med. 296:7-10, 1977.
34. Baker, H.W.G., Bailey, D.J., Worgul, T.J., Jefferson, L.S., Santen, R.J., Bardin, C.W. Evaluation of methods for perfusing rat testes. Invest. Urol. 15:169-172, 1977.
35. Santen, R.J., Samojlik, E., Lipton, A., Harvey, H., Ruby, E., Wells, S.A., Kendall, J. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 39:2948-2958, 1977.
36. Santen, R.J., Wells, S.A., Runic, S., Gupta, C., Kendall, J., Ruby, E.B., Samojlik, E. Adrenal suppression with aminoglutethimide. I. Differential effects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. J. Clin. Endocrinol. Metab. 45:469-479, 1977.
37. Samojlik, E., Santen, R.J., Wells, S.A. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J. Clin. Endocrinol. Metab. 45:480-487, 1977.
38. Santen, R.J., Wells, S.A., Cohn, N., Demers, L.M., Misbin, R.I., Foltz, E.L. Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. J. Clin. Endocrinol. Metab. 45:739-746, 1977.
39. Sanford, E.J., Paulson, D.F., Rohner, T.J., Drago, J.R., Santen, R.J., Bardin, C.W. The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J. Urol. 118:1019-1021, 1977.
40. Santen, R.J. Hormone responsiveness in breast cancer. IN: Consultant, pp. 47-54, May, 1978.
41. Bardin, C.W., Baker, H.W.G., Jefferson, L.S., Santen, R.J. Methods for perfusing the male reproductive tract: Models for studying drug and hormone metabolism. Environmental Health Perspectives 24:51-59, 1978.
42. Santen, R.J., Friend, J.N., Trojanowski, D., Davis, B., Samojlik, E., Bardin, C.W. Prolonged negative feedback suppression after estradiol administration: Proposed mechanism of eugonadal secondary amenorrhea. J. Clin. Endocrinol. Metab. 47:1220-1229, 1978.
43. Wells, S.A., Santen, R.J., Lipton, A., Haagensen, D., Ruby, E.J., Harvey, H., Dilley, W.G. Medical adrenalectomy with aminoglutethimide: Clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann. Surg. 187:475-484, 1978.
44. Samojlik, E., Santen, R.J. Adrenal suppression with aminoglutethimide III. Comparison of plasma 4- and 5-steroids in postmenopausal women treated for breast carcinoma. J. Clin. Endocrinol. Metab. 47:717-724, 1978.
45. Santen, R.J., Santner, S., Davis, B., Veldhuis, J., Samojlik, E., Ruby, E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. J. Clin. Endocrinol. Metab. 47:1257-1265, 1978.
46. Santner, S.J., Murray, F.T., Davis, B., Santen, R.J. The integrated gonadotropin test. Ann.

Int. Med. 89:512-513, 1978.

47. Lawrence, B., Santen, R.J., Lipton, A., Harvey, H.A., Hamilton, R., Mercurio, T. Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. Cancer Treatment Reports 62:1581-1583, 1978.

48. Musto, N.A., Santen, R.J., Huckins, C., Bardin, C.W. Abnormalities of the pituitary-gonadal-axis of H^{re} rats: A study of animals with an inherited disorder of seminiferous tubular and Leydig cell function. Biol. Reprod. 19:797-806, 1978.

49. Harvey, H.A., Santen, R.J., Osterman, J., Samojlik, E., White, D., Lipton, A. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43:2207-2214, 1979.

50. Santen, R.J., Cohn, N., Misbin, R., Samojlik, E., Foltz, E. Acute effects of aminoglutethimide on testicular steroidogenesis in normal men. J. Clin. Endocrinol. Metab. 49:631-634, 1979.

51. Gupta, C., Osterman, J., Santen, R., Bardin, C.W. *In vivo* metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rates and volume of distribution of medroxyprogesterone acetate in women. J. Clin. Endocrinol. Metab. 48:816-820, 1979.

52. Veldhuis, J.D., Santen, R.M.; Current therapy of hypopituitarism. Current Therapy 31:460-464, 1979.

53. Veldhuis, J.D., Santen, R.J. Pituitary pseudotumor: Mimicry of recurrent prolactinoma by a chronic intrasellar hematoma. Arch. Int. Med. 139:1309-1311, 1979.

54. Santen, R.J., Ruby, E.R. Enhanced frequency and magnitude of episodic LH-RH discharge as a hypothalamic mechanism for increased LH secretion. J. Clin. Endocrinol. Metab. 48:315-319, 1979.

55. Santen, R.J., Veldhuis, J.D., Samojlik, E., Lipton, A., Harvey, H., Wells, S.A. Mechanism of action of aminoglutethimide in breast cancer. Lancet i:44-45, 1979.

56. Veldhuis, J.D., Santen, R.J. (letter) Tamoxifen flare. JAMA 241:2506-2507, 1979.

57. Franchimont, P., Demoulin, A., Bourguignon, J.P., Santen, R.J. Role of Inhibin in the regulation of gonadotrophin secretion in the male. Pediatr. Adolesc. Endocrinol. 6:47-63, 1979.

58. Badder, E.M., Santen, R.J., Seaton, J.F., Harrison, T.S. Inhibition of adrenal medullary secretion by adrenal cortical suppression. Surg. Forum 30:98-100, 1979.

59. Murray, F.T., Santner, S., Samojlik, E., Santen, R.J. Serum aminoglutethimide levels: Studies of serum half-life, clearance and patient compliance. J. Clin. Pharmacol. 19:704-711, 1979.

60. Lawrence, B.V., Lipton, A., Harvey, H.A., Santen, R.J., Wells, S.A., Cox, C.E., White, D., Smart, E.K. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer 45:786-791, 1980.

61. Veldhuis, J.D., Kulin, H.E., Santen, R.J., Wilson, T.E., Melby, J.C. Inborn error in the terminal step of aldosterone biosynthesis: Corticosterone methyloxidase type II deficiency in a North American pedigree. N. Engl. J. Med. 303:117-121, 1980.
62. Santen, R.J., Wells, Jr., S.A. The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 46:1066-1074, 1980.
63. Santen, R.J., Collette, J., Franchimont, P. Partial purification of carcino-embryonic-reactive antigen from breast neoplasms using lectin and antibody affinity chromatography. Cancer Res. 40:1181-1188, 1980.
64. Santen, R.J., Samojlik, E., Demers, L., Badder, E. Adrenal of the male dog secretes androgens and estrogens. Am. J. Physiol. 239:E109-E112, 1980.
65. Samojlik, E., Veldhuis, J.D., Wells, S.A., Santen, R.J. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J. Clin. Invest. 65:602-612, 1980.
66. Santen, R.J., Samojlik, E., Wells, S.A. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J. Clin. Endocrinol. Metab. 51:473-477, 1980.
67. Samojlik, E., Santen, R.J. Potency of the D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis. J. Clin. Endocrinol. Metab. 51:462-465, 1980.
68. Badder, E.M., Santen, R., Samojlik, E., Harrison, T.S. Adrenal medullary epinephrine secretion: Effects of cortisol alone and combined with aminoglutethimide. J. Lab. Clin. Med. 96:815-821, 1980.
69. Linehan, W.M., Cooper, C.W., Green, J.E., Garbutt, J.T., Santen, R.J., Wells, S.A. Stimulation of gastrin release by calcium, secretin, and calcium plus secretin in patients with Zollinger-Ellison syndrome. Surg. Forum XXXI:175-177, 1980.
70. Franchimont, P., Demoulin, A., Bourguignon, J.P., Santen, R. The regulation of gonadotrophin secretion in male. Annales d'Endocrinologie 41(3):231-232, 1980.
71. Demers, L.M., Harrison, T.S., Halbert, D.R., Santen, R.J. Effect of prolonged exercise on plasma prostaglandin levels. Prostaglandins Med. 6:413-418, 1981.
72. Warner, B.A., Santen, R.J. Response to TRH in FSH secreting adenomas: An example of hormone cross-talk. Lancet ii:42, 1981. (Letter)
73. Worgul, T.J., Kendall, J., Santen, R.J. Recovery of hypothalamic-pituitary-adrenal function after long-term suppression by aminoglutethimide and hydrocortisone. J. Clin. Endocrinol. Metab. 53:879-882, 1981.
74. Santen, R.J., Worgul, T.J., Samojlik, E., Interrante, A., Boucher, A.E., Lipton, A., Harvey, H.A., White, D.S., Smart, E., Cox, C., Wells, S. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N. Engl. J. Med. 305:545-551, 1981.
75. Harrison, T.S., Santen, R.J., Maruca, J. Calcium stimulation test in the evaluation of insulin

- secreting pancreatic islet cell tumors. Case Reports: Military Medicine 146:103-105, 1981.
76. Santen, R.J., Misbin, R.I. Aminoglutethimide: Review of pharmacology and clinical use. Pharmacotherapy 1:95-120, 1981.
77. Santen, R.J. Feedback control of luteinizing hormone and follicle-stimulating hormone secretion by testosterone and estradiol in men: Physiologic and clinical implications. Clin. Biochem. 14:243-251, 1981.
78. Kulin, H.E., Samojlik, E., Santen, R., Santner, S. The effect of growth hormone on the Leydig cell response to chorionic gonadotrophin in boys with hypopituitarism. Clin. Endocrinol. 15:463-472, 1981.
79. Worgul, T.J., Santen, R.J., Samojlik, E., Irwin, G., Falvo, R.E. Evidence that brain aromatization regulates LH secretion in the male dog. Amer. J. Physiol. 241:E246-E250, 1981.
80. Santen, R.J. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review. Br. Cancer Res. Treat. 1:183-202, 1981.
81. Santen, R.J., Veldhuis, J.D., Harvey, H.A., Lipton, A. Chemotherapy and tamoxifen for breast cancer. N. Engl. J. Med. 305:1014, 1981.
82. Santner, S.J., Santen, R.J., Kulin, H.E., Demers, L.M. A model for validation of radioimmunoassay kit reagents: Measurement of follitropin and lutropin in blood and urine. Clin. Chem. 27:1892-1895, 1981.
83. Worgul, T.J., Santen, R.J., Samojlik, E., Wells, S.A. How effective is surgical adrenalectomy in lowering steroid hormone concentrations. J. Clin. Endocrinol. Metab. 54:22-26, 1982.
84. Lipton, A., Harvey, H.A., Santen, R.J., Boucher, A., White, D., Bernath, A., Dixon, R., Richards, G., Shafik, A. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50:2265-2268, 1982.
85. Warner, B.A., Santen, R.J., Page, R.B. Growth hormone and prolactin secretion by a tumor of the pharyngeal pituitary. Ann. Int. Med. 96:65-66, 1982.
86. Cadieux, R.J., Kales, A., Santen, R.J., Bixler, E.O., Gordon, R. Endoscopic findings in sleep apnea associated with acromegaly. J. Clin. Endocrinol. Metab. 55:18-22, 1982.
87. Santen, R.J., Worgul, T.J., Lipton, A., Harvey, H., Boucher, A., Samojlik, E., Wells, S.A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann. Int. Med. 96:94-101, 1982.
88. Samojlik, E., Santen, R.J., Worgul, T.J. Plasma estrone-sulfate: Assessment of reduced estrogen production during treatment of metastatic breast carcinoma. Steroids 39:497-507, 1982.
89. Santen, R.J., Santner, S.J., Tilsen-Mallett, N., Rosen, H.R., Samojlik, E., Veldhuis, J.D. *In vivo* and *in vitro* pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Res. 42:3353S-3359S, 1982.

90. Santen, R.J., Worgul, T.J., Samojlik, E., Boucher, A.E., Lipton, A., Harvey, H. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: Correlation of hormonal data with clinical responses. Cancer Res. 42:3397S-3401S, 1982.
91. Samojlik, E., Santen, R.J., Kirschner, M.A., Ertel, M.H. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast. Cancer Res. 42:3349S-3352S, 1982.
92. Wells, Jr., S.A., Worgul, T.J., Samojlik, E., Boucher, A.E., Lipton, A., Harvey, H., White, D., Smart, E., Cox, C., Santen, R.J. Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast. Cancer Res. 42:3454S-3457S, 1982.
93. Harvey, H.A., Lipton, A., White, D.S., Santen, R.J., Boucher, A.E., Shafik, A.S., Dixon, R.J., and Members of The Central Pennsylvania Oncology Group. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res. 42:3451S-3453S, 1982.
94. Stumpf, P.G., Maruca, J., Santen, R.J., Demers, L.M. Development of a vaginal ring for achieving physiologic levels of 17 β -estradiol in hypoestrogenic women. J. Clin. Endocrinol. Metab. 54:208-210, 1982.
95. Santen, R.J., Badder, E., Lerman, S., Harvey, H., Lipton, A., Boucher, A.E., Manni, A., Rosen, H., Wells, S.A. Pharmacologic suppression of estrogens with aminoglutethimide as treatment of advanced breast carcinoma: Mechanistic, hormonal and clinical studies. Br. Cancer Res. Treat. 2:375-383, 1982.
96. Warner, B.A., Santen, R.J. Asymptomatic primary hyperparathyroidism. Ann. Int. Med. 97:142-143, 1982.
97. Lipton, A., Harvey, H.A., Santen, R.J., Boucher, A., White, D., Bernath, A., Dixon, R., Richards, G., Shafik, A. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 42:3434s-3436s, 1982.
98. Santen, R.J. Overall experience with aminoglutethimide in the management of advanced breast carcinoma. IN: Intl. Cong. and Symp. Ser. 53: Aminoglutethimide: An Alternative Endocrine Therapy for Breast Carcinoma, R.W. Elsdon-Dew, I.M. Jackson and G.F.B Birdwood (ed), Royal Society of Medicine/Academic Press/Grune and Stratton, London/New York, pp. 3-7, 1982.
99. Worgul, T.J., Santen, R.J., Samojlik, E., Veldhius, J.D., Lipton, A., Harvey, H.A., Drago, J.R., Rohner, T.J. Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J. Urol. 129:51-55, 1983.
100. Romanus, M.E., Neal, J.A., Dilley, W.G., Leight, G.S., Linehan, W.M., Santen, R.J., Farndon, J.R., Jones, R.S., Wells, Jr., S.A. Comparison of four provocative tests for the diagnosis of gastrinoma. Ann. Surg. 197:608-617, 1983.
101. Warner, B.A., Worgul, T.J., Drago, J., Demers, L.M., Dufau, M., Max, D., Santen, R.J., and Members of the Abbott Study Group. Effect of very high dose D-Leu⁶-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with

prostatic cancer. J. Clin. Invest. 71:1842-1853, 1983.

102. Santen, R.J., Lipton, A., Harvey, H., Boucher, A.E., Henderson, C. Pharmacologic mechanisms of estrogen suppression with aminoglutethimide in women with breast cancer. Proc. 13th Intl. Cong. Chemotherapy, Vienna, Austria, Aug. 28, 1983-Sept. 2, 1983, pp. 218/21-25, 1983.

103. Harvey, H.A., Lipton, A., Santen, R.J. Clinical studies with aminoglutethimide in advanced carcinoma. Proc. 13th Intl. Cong. Chemotherapy, Vienna, Austria, Aug. 28, 1983-Sept. 2, 1983, pp. 218/35-40, 1983.

104. Tilson-Mallett, N., Santner, S.J., Feil, P.D., Santen, R.J. Biological significance of aromatase activity in human breast tumors. J. Clin. Endocrinol. Metab. 57:1125-1128, 1983.

105. English, H.F., Schanbacher, B.D., Gross, D., Walker, M.F., Falvo, R.E., Santen, R.J. Animal model of isolated gonadotrophin deficiency: II. Morphologic responses to LHRH immunoneutralization. J. Androl. 4:240-247, 1983

106. Schanbacher, B.D., English, H.F., Gross, D., Santen, R.J., Walker, M.F., Falvo, R.E. Animal model of isolated gonadotropin deficiency: I. Hormonal response to LHRH immunoneutralization. J. Androl. 4:233-239, 1983.

107. Santen, R.J., Van den Bossche, H., Symoens, J., Brugmans, J., DeCoster, R. Site of action of low-dose ketoconazole on androgen biosynthesis in men. J. Clin. Endocrinol. Metab. 57:732-736, 1983.

108. Lipton, A., Harvey, H.A., Santen, R.J. Aminoglutethimide as an alternative to surgical adrenalectomy in elderly women with metastatic breast cancer. Ger. Med. Today 2:25-28, 1983.

109. Manni, A., Latshaw, R.F., Page, R., Santen, R.J. Simultaneous bilateral venous sampling for ACTH in pituitary-dependent Cushing's Disease. Evidence for lateralization of pituitary venous drainage. J. Clin. Endocrinol. Metab. 57:1070-1073, 1983.

110. Badder, E.M., Lerman, S., Santen, R.J. Aminoglutethimide stimulates extra adrenal delta-4 androstenedione production. J. Surg. Res. 34:380-387, 1983.

111. Santen, R.J., Demers, L.M., Max, D.T., Smith, J., Stein, B.S., Glode, L.M. Long-term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. J. Clin. Endocrinol. Metab. 58:397-400, 1984.

112. Samojlik, E., Santen, R.J., Worgul, T.J. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. Clin. Endocrinol. 20:43-51, 1984.

113. Santner, S.J., Rosen, H., Osawa, Y., Santen, R.J. Additive effects of aminoglutethimide, testololactone, and 4-hydroxy-androstenedione as inhibitors of aromatase. J. Steroid Biochem. 20:1239-1242, 1984.

114. Santner, S.J., Feil, P.D., Santen, R.J. *In situ* estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59:29-33, 1984.

115. Manni, A., Santen, R.J., Boucher, A., Lipton, A., Harvey, H., Drago, J., Rohner, T., Haagensen, D., Glode, M., Santner, S.J. Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation. Anticancer Res. 4:141-144, 1984.
116. Harrison, T.S., Fajans, S.S., Floyd, Jr., J.C., Thompson, N.W., Rasbach, D.A., Santen, R.J., Cohen, C. Prevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism - Problems in recognition and management. World J. Surg. 8:583-589, 1984.
117. Wells, S.A., Santen, R.J. Ablative procedures in patients with metastatic breast carcinoma. Cancer 53:762-765, 1984.
118. Lipton, A., Santen, R.J., Harvey, H.A. Aminoglutethimid beim metastasierenden mammarkarzinom. IN: Aktuelle Onkologie 9, G.A. Nagel, R. Sauer and H.W. Schreiber (ed), W. Zuckschwerdt Verlag Munchen, Bern, pp. 20-34, 1984.
119. Drago, J.R., Santen, R.J., Lipton, A., Worgul, T.J., Harvey, H.A., Boucher, A. Manni, A., Rohner, T.J. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 53:1447-1450, 1984.
120. Maruca, J., Santner, S., Miller, K., Santen, R.J. Prolonged iodine clearance with a depletion regimen for thyroid carcinoma: Concise communication. J. Nucl. Med. 25:1089-1093, 1984.
121. Santen, R.J. Aminoglutethimide as an aromatase inhibitor in the treatment of cancer. Cancer Treat. Rev. 11:325-329, 1984.
122. Lookingbill, D.P., Horton, R., Demers, L.M., Egan, N., Marks, Jr., J.G., Santen, R.J. Tissue production of androgens in women with acne. J. Am. Acad. Dermatol. 12:481-487, 1985.
123. Warner, B.A., Dufau, M.L., Santen, R.J. Effects of aging and illness on the pituitary testicular axis in men: Qualitative as well as quantitative changes in LH. J. Clin. Endocrinol. Metab. 60:263-268, 1985.
124. Santen, R.J., Warner, B. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (Leuprolide) on testicular androgen production in patients with carcinoma of prostate. Urology XXV(Suppl.):53-57, 1985.
125. Plourde, P.V., Dufau, M., Plourde, N., Santen, R.J. Impotence associated with low biological to immunological ratio of luteinizing hormone in a man with a pituitary stone. J. Clin. Endocrinol. Metab. 60:797-802, 1985.
126. Manni, A., Santen, R.J., Boucher, A., Lipton, A., Harvey, H., Simmonds, M., White, D., Gordon, R., Rohner, T., Drago, J., Wettlaufer, J., Glode, L.M. Hormone stimulation and chemotherapy in advanced prostate cancer: Preliminary results of a prospective controlled clinical trial. Anticancer Res. 5:161-166, 1985.
127. Dowsett, M., Jeffcoate, S.L., Santner, S., Santen, R.J., Stuart-Harris, R., Smith, I.E. Low-dose aminoglutethimide and aromatase inhibition. Lancet i:175-176, 1985.
128. English, H.F., Santner, S., Levine, H.B., Santen, R.J. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in

the rat. Cancer Res. 46:38-42, 1986.

129. Dowsett, M., Santner, S.J., Santen, R.J., Jeffcoate, S.L., Smith, I.E. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. Brit. J. Cancer 52:31-35, 1985.

130. Messeih, A.A., Lipton, A., Santen, R.J., Harvey, H.A., Boucher, A.E., Murray, R., Ragaz, J., Buzdar, A.U., Nagel, G.A., Henderson, I.C. Aminoglutethimide-induced hematologic toxicity: Worldwide experience. Cancer Treat. Rep. 69:1003-1004, 1985.

131. Manni, A., Pardridge, W.M., Cefalu, W., Nisula, B.C., Bardin, C.W., Santner, S.J., Santen, R.J. Bioavailability of albumin-bound testosterone. J. Clin. Endocrinol. Metab. 61:705-710, 1985.

132. English, H.F., Drago, J.R., Santen, R.J. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. The Prostate 7:41-51, 1985.

133. White, D.P., Schneider, B.K., Santen, R.J., McDermott, M., Pickett, C.K., Zwillich, C.W., Weil, J.V. Influence of testosterone on ventilation and chemosensitivity in male subjects. J. Appl. Physiol. 59:1452-1457, 1985.

134. Cutler, Jr., G.B., Hoffman, A.R., Swerdloff, R.S., Santen, R.J., Meldrum, D.R., Comite, F. NIH Conference: Therapeutic applications of luteinizing-hormone-releasing hormone and its analogs. Ann. Int. Med. 102:643-657, 1985.

135. Drago, J.R., Rohner, T., Santen, R., Manni, A., Lipton, A., Harvey, H., English, H. Leuprolide: a review of its effects in animal and man. British Journal of Clinical Practice Supplement 37:4-7, 16-19, 1985.

136. Drago, J.R., Rohner, T., Santen, R., Manni, A., English, H., Lipton, A., Harvey, H.. Leuprolide: a review of its effects in animal and man. British Journal of Clinical Practice 39(2):77-79, 1985.

137. Santner, S.J., Leszczynski, D., Wright, C., Manni, A., Feil, P.D., Santen, R.J. Estrone sulfate: A potential source of estradiol in human breast cancer tissues. Breast Cancer Res. Treat. 7:35-44, 1986.

138. Manni, A., Santen, R., Harvey, H., Lipton, A., Max, D. Treatment of breast cancer with GnRH. Endocrine Rev. 7:89-94, 1986.

139. Buchanan, J.R., Santen, R.J., Cavaliere, A., Cauffman, S.W., Greer, R.B., Demers, L.M. Interaction between parathyroid hormone and endogenous estrogen in normal women. Metabolism 35:489-494, 1986.

140. Buchanan, J.R., Santen, R., Cauffman, S., Cavaliere, A., Greer, R.B., Demers, L.M. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcified Tissue Intl. 39:139-144, 1986.

141. Brunt, L.M., Veldhuis, J.D., Dilley, W.G., Farndon, J.R., Santen, R.J., Leight, G.S., Wells, Jr., S.A. Stimulation of insulin secretion by a rapid intravenous calcium infusion in patients with

beta cell neoplasms of the pancreas. J. Clin. Endocrinol. Metab. 62:210-216, 1986.

142. Santen, R.J. Aromatase inhibitors for treatment of breast cancer: Current concepts and new perspectives. Breast Cancer Res. Treat (Suppl.) 7:23-36, 1986.

143. English, H.F., Kloszewski, E.D., Valentine, E., Santen, R.J. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res. 46:839-844, 1986.

144. Manni, A., Basarab, R.M., Plourde, P.V., Koivunen, D., Harrison, T.S., Santen, R.J. Thallium-technetium parathyroid scan: A useful noninvasive technique for localization of abnormal parathyroid tissue. Arch. Int. Med. 146:1077-1080, 1986.

145. Santen, R.J., Swerdloff, R.S. (ed). Male Reproductive Dysfunction: Diagnosis and Management of Hypogonadism, Infertility, and Impotence, Marcel Dekker, Inc., New York, 1986.

146. Manni, A., Santen, R.J., Boucher, A.E., Lipton, A., Harvey, H., Simmonds, M., White-Hershey, D., Gordon, R.A., Rohner, T., Drago, J., Wettlaufer, J., Glode, L.M. Hormone stimulation and chemotherapy in advanced prostate cancer: Interim analysis of an ongoing randomized trial. Anticancer Res. 6:309-314, 1986.

147. Santen, R.J., Manni, A., Harvey, H. Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res. Treat. 7:129-145, 1986.

148. Manni, A., Santen, R.J., Boucher, A.E., Lipton, A., Harvey, H., Simmonds, M., White-Hershey, D., Gordon, R.A., Rohner, T.J., Drago, J., Wettlaufer, J., Glode, L.M. Androgen priming and response to chemotherapy in advanced prostatic cancer. J. Urol. 136:1242-1246, 1986.

149. Harvey, H., Lipton, A., Santen, R. Clinical studies with aminoglutethimide in advanced breast carcinoma. Acta Clin. Belgica 41:29-40, 1986.

150. Schneider, B.K., Pickett, C.K., Zwillich, C.W., Weill, J.W., McDermott, M.T., Santen, R.G., Varano, L.A., White, D.P. The influence of testosterone on breathing during sleep. J. Appl. Physiol. 61:618-623, 1986.

151. Marx, S.J., Vinik, A.I., Santen, R.J., Floyd, J.C., Mills, J., Green III, J. Multiple endocrine neoplasia type I: Assessment of laboratory tests to screen for the gene in a large kindred. Medicine 65:226-241, 1986.

152. Lipton, A., Santner, S.J., Santen, R.J., Harvey, H.A., Feil, P.D., White-Hershey, D., Bartholomew, M.J., Antle, C.E. Aromatase activity in primary and metastatic human breast cancer. Cancer 59:779-782, 1987.

153. Santen, R.J., Boucher, A.E., Santner, S.J., Henderson, I.C., Harvey, H., Lipton, A. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women. J. Lab. Clin. Med. 109:278-289, 1987.

154. Lipton, A., Santen, R.J., Harvey, H.A., Manni, A., Simmonds, M.A., White-Hershey, D.S., Bartholomew, M.S., Walker, B.K., Dixon, R.H., Valdevia, D.E., Gordon, R.A. A randomized

trial of aminoglutethimide \pm estrogen prior to chemotherapy in advanced breast cancer. J. Clin. Oncol. 10:65-70, 1987.

155. Demers, L.M., Boucher, A.E., Santen, R.J. Aminoglutethimide therapy in breast cancer: Relationship of blood levels to drug-related side effects. Clin. Physiol. Biochem. 5:287-291, 1987.

156. Levin, M., Weisz, J., Bui, Q.D., Santen, R.J. Peroxidatic catecholestrogen production by human breast cancer tissue *in vitro*. J. Steroid Biochem. 28:513-520, 1987.

157. English, H.F., Santen, R.J., Isaacs, J.T. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. The Prostate 11:229-242, 1987.

158. Santen, R.J., Mowszowicz, I., Portois, M.C., Mauvais-Jarvis, P. Androgen dependence of the Dunning R3327G cell line in monolayer culture. The Prostate 11:377-387, 1987.

159. Manni, A., Santen, R.J., Boucher, A.E., Lipton, A., Harvey, H., Simmonds, M., Gordon, R., Rohner, T., Drago, J., Wettlaufer, J., Glode, L.M. Androgen depletion and repletion as a means of potentiating the effects of cytotoxic chemotherapy in advanced prostate cancer. J. Steroid Biochem. 27:511-556, 1987.

160. Davis, M., Nassberg, B., Borges, J.L.C., Iranmanesh, A., Lizzaralde, G., Santen, R.J., Drake, C., Rogol, A.D., Kaiser, D.L., Thorner, M.O., Veldhuis, J.D. Actions of calcium ions and a calcium-influx blocker on basal and TRH- and GnRH-stimulated hormone release in patients with pituitary adenomas. J. Endocrinol. Invest. 10:427-433, 1987.

161. Lipton, A., Santen, R.J., Harvey, H.A. Aminoglutethimide therapy of breast cancer and prostate cancer. Primary Care and Cancer 7:110R-150R, 1987.

162. Santen, R.J. Potential clinical role of new aromatase inhibitors. Steroids 50:575-593, 1987.

163. Ahmed, S.R., Boucher, A.E., Manni, A., Santen, R.J., Bartholomew, M., Demers, L.M. Transdermal testosterone therapy in the treatment of male hypogonadism. J. Clin. Endocrinol. Metab. 66:546-551, 1988.

164. Manni A., Bartholomew, M., Caplan, R., Boucher, A., Santen, R., Lipton, A., Harvey, H., Simmonds, M., White-Hershey, D., Gordon, R., Rohner, T., Drago, J., Wettlaufer, J., Glode, L. Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. J. Clin. Oncol. 6:1456-1466, 1988.

165. Lipton A., Santen, R.J., Santner, S.J., Harvey, H.A., White-Hershey, D., Bartholomew, M.J., Sharkey, F.E. Correlation of aromatase activity with histological differentiation of breast cancer--A morphometric analysis. Breast Cancer Res. Treat. 12:31-35, 1988.

166. Leszczynski D., Santner, S.J., Feil, P.D., Santen, R.J. 17 β -hydroxysteroid dehydrogenase in human breast cancer: Analysis of kinetic and clinical parameters. Steroids 51:299-316, 1988.

167. Santen R.J., Santner, S.J., Harvey, H.A., Lipton, A., Simmonds, M., Feil, P.D., Manders, E., Davis, T.S. Marked heterogeneity of aromatase activity in human malignant melanoma

tissue. Eur. J. Cancer Clin. Oncol. 24:1811-1816, 1988.

168. Lookingbill, D.P., Egan, N., Santen, R.J., Demers, L.M. Correlation of serum 3 α -androstane diol glucuronide with acne and chest hair density in men. J. Clin. Endocrinol. Metab. 67:986-991, 1988.

169. Santen R.J., Demers, L.M., Adlercreutz, H., Harvey, H., Santner, S., Sanders, S., Lipton, A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J. Clin. Endocrinol. Metab. 68:99-106, 1989.

170. Santen, R.J. Editorial: Hormonal therapy of prostate cancer: Choosing among several available options. Intl. J. Androl. 12:165-170, 1989.

171. Santen, R.J. Novel methods of oestrogen deprivation for treatment of breast disease. Proc. Royal Soc. Edinburgh 95B: 255-269, 1989.

172. Santen, R.J., Langecker, P., Santner, S., Sikka, S., Swerdloff, R. Potency and specificity of CGS-16949A as an aromatase inhibitor. Endocrinol. Res. 16:77-91, 1990.

173. Wild, R.A., Applebaum-Bowden, D., Demers, L.M., Bartholomew, M., Landis, J.R., Hazzard, W.R., Santen, R.J. Lipoprotein lipids in women with androgen excess: Independent associations with increased insulin and androgen. Clin. Chem. 36:283-289, 1990.

174. Demers, L.M., Melby, J.C., Wilson, T.E., Lipton, A., Harvey, H.A., Santen, R.J. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid bio-synthesis. J. Clin. Endocrinol. Metab. 70:1162-1166, 1990.

175. Lipton, A., Harvey, H.A., Santen, R.J., Stryker, J.A., Barnes, S.G., Walerk, B.K., Dixon, R.H., Givant, E.M., Bartholomew, M.J., Nadjafi, C. FAM chemotherapy \pm aminoglutethimide in the treatment of pancreatic carcinoma. Eur. J. Surg. Oncol. 16:12-14, 1990.

176. Lipton, A., Harvey, H.A., Demers, L.M., Hanagan, J.R., Mulagha, M.T., Kochak, G.M., Fitzsimmons, S., Sanders, S.I., Santen, R.J. A phase I trial of CGS 16949A - A new aromatase inhibitor. Cancer 65:1279-1285, 1990.

177. Simons, R.J., Simon, J.M., Demers, L.M., Santen, R.J. Thyroid dysfunction in elderly hospitalized patients: Effect of age and severity of illness. Arch. Int. Med. 150:1249-1253, 1990.

178. Santen, R.J., Manni, A., Harvey, H., Redmond, C. Endocrine treatment of breast cancer in women. Endocrinol. Rev. 11:221-265, 1990.

179. Santner, S.J., Levin, M.C., Santen, R.J. Estrone sulfate stimulates growth of nitrosomethylurea-induced breast carcinoma *in vivo* in the rat. Intl. J. Cancer 46:73-78, 1990.

180. Santen, R.J. Clinical use of aromatase inhibitors: Current data and future perspectives. J. Enzyme Inhibition 4:79-99, 1990.

181. Kochak, G.M, Mangat, S., Mulagha, M.T., Entwistle, E.A., Santen, R.J., Lipton, A., Demers, L. The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. J. Clin. Endocrinol. Metab. 71:1349-1355, 1990.

182. Santen, R.J., Manni, A., English, H.F., Heitjan, D. Androgen-primed chemotherapy - experimental confirmation of efficacy. J. Steroid Biochem. Molec. Biol. 37:1115-120, 1990.
183. Santen, R.J. Recent progress in development of aromatase inhibitors. J. Steroid Biochem. Molec. Biol. 37:1029-1035, 1990.
184. Coen, P., Kulin, H., Ballantine, T., Zaino, R., Frauenhoffer, E., Boal, D., Inkster, S., Brodie, A., Santen, R.J. An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. New England Journal of Medicine 324:317-322, 1991.
185. English, H.F., Heitjan, D.F., Lancaster, S., Santen, R.J. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer. Cancer Research 51:1760-1765, 1991.
186. Lookingbill, D.P., Demers, L.M., Wang, C., Leung, A., Rittmaster, R.S., Santen, R.J. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Endocrinol. Metab. 72:1242-1248, 1991.
187. Bardin, C.W., Swerdloff, R.S., Santen, R.J. Androgens: Risks and benefits. J. Clin. Endocrinol. Metab. 73:4-7, 1991.
188. Santen, R.J., Demers, L.M., Lynch, J., Harvey, H., Lipton, A., Mulagha, M., Hanagan, J., Garber, J.E., Henderson, I.C., Navari, R.M., Miller, A.A. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J. Clin. Endocrinol. Metab. 73:99-106, 1991.
189. Santen, R.J. Clinical use of aromatase inhibitors in human breast carcinoma. J. Steroid. Biochem. Molec. Biol. 40:247-253, 1991.
190. Brackett, L.E., Demers, L.M., Mamourian, A.C., Ellenberger Jr., C., Santen, R.J. Moebius syndrome in association with hypogonadotropic hypogonadism. J. Endocrinol. Invest. 14:599-607, 1991.
191. Santen, R.J. Solving the puzzle of hormone-dependent breast cancer. Trans. Am. Clin. Climatol. Assoc. 103:164-175, 1992.
192. Santen, R.J. Endocrine treatment of prostate cancer. J. Clin. Endocrinol. Metab. 75:685-689, 1992.
193. Santen, R.J. Endocrine treatment of prostate cancer. The Endocrinologist 2:384-391, 1992.
194. Lipton, A., Santen, R.J., Santner, S.J., Harvey, H.A., Sanders, S.I., Matthews, Y.L. Prognostic value of breast cancer aromatase. Cancer 70:1951-1955, 1992.
195. Demers, L.M., Lipton, A., Harvey, H.A., Kambic, K.B., Grossberg, H., Brady, C., Santen, R.J. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J. Steroid Biochem. Molec. Biol. 44:647-649, 1993.
196. Demers, L.M., Lipton, A., Harvey, H.A., Hanagan, J., Mulagha, M., Santen, R.J. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast

- cancer. J. Steroid Biochem. Molec. Biol. 44:683-685, 1993.
197. Santner, S.J., Chen, S., Zhou, D., Korsunsky, Z., Martel, J., Santen, R.J. Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J. Steroid Biochem. Molec. Biol. 44:611-616, 1993.
198. Berstein, L.M., Santner, S.J., Brodie, A.M., Koos, R.D., Naftolin, F., Santen, R.J. Pseudoaromatase in circulating lymphocytes. Proc. 3rd Intl. Aromatase Conference, Bologna, Italy, J. Steroid Biochem. Molec. Biol. 44:647-649, 1993.
199. Santner, S.J., Ohlsson-Wilhelm, B., Santen, R.J. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int. J. Cancer 54:119-124, 1993.
200. Santner, S.J., Santen, R.J. Inhibition of estrone sulfatase and 17beta-hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Molec. Biol. 45:383-390, 1993.
201. Ahmed, S.R., Aiello, D.P., Page, R., Hopper, K., Towfighi, J., Santen, R.J. Necrotizing infundibulo-hypophysitis: A new syndrome of diabetes insipidus and hypopituitarism. J. Clin. Endocrinol. Metabol. 76:1499-1504, 1993.
202. Santen, R.J. Editorial: Estrogen synthesis inhibitors: From "off the rack" to haute couture. J. Clin. Endocrinol. Metabol. 77:316-318, 1993.
203. Heitjan, D.F., Manni, A., Santen, R.J. Statistical analysis of *in vivo* tumor growth experiments. Cancer Res. 53:6042-6050, 1993.
204. Brodie, A.M.H., Santen, R.J. Aromatase and its inhibitors in breast cancer treatment -- Overview and perspective. Breast Cancer Res. Treat. 30:1-6, 1994.
205. Santen, R.J., Martel, J., Hoagland, M., Naftolin, F., Roa, L., Harada, N., Hafer, L., Zaino, R., Santner, S.J. Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 79:627-632, 1994.
206. Masamura, S., Adlercreutz, H., Harvey, H., Lipton, A., Demers L.M., Santen, R.J., Santner, S.J. Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res. Treat. 33:19-26, 1994.
207. Harvey, H.A., Lipton, A., Santen, R.J., Demers, L., Henderson, I.C., Garber, J.E., Miller, A.A., Navari, R., Mulagha, M., Hanagan, J. Phase I and phase II clinical trials of fadrozole hydrochloride in postmenopausal women with metastatic breast cancer. Adv. Clin. Oncol. 2:155-158, 1994.
208. Lipton, A., Demers, L.M., Harvey, H.A., Kambic, K.B., Grossberg, H., Brady, C., Adlercruetz, H., Trunet, P.F., and Santen, R.J. Letrozole (CGS 20267) - Phase 1 study of a new potent oral aromatase inhibitor in breast cancer. Cancer 75:2132-2138, 1995.
209. Masamura, S., Santner, S.J., Heitjan, D.F., Santen, R.J. Estrogen deprivation causes estradiol hypersensitivity in human cancer cells. J. Clin. Endocrinol. Metab. 80:2918-2925, 1995.

210. Berstein, L., Santen, R.J., Santner, S.J. Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms. Med. Hypoth. 45:588-598, 1995.
211. Oerter-Klein, K., Demers, L.M., Santner, S.J., Baron, J., Cutler, Jr., G.B., Santen, R.J. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J. Clin. Endocrinol. Metab. 80:2658-2660, 1995.
212. Santen, R.J. Estrogen synthesis inhibitors for breast cancer: An introductory overview. Endocrine-Related Cancer. 3:1-8, 1996.
213. Masamura, S., Santner, S.J., Santen, R.J. Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J. Steroid Biochem. Molec. Biol., 58:425-429, 1996.
214. Yue, W., Santen, R.J. Aromatase Inhibitors: Rationale for use following antiestrogen therapy, Seminars in Oncology, 23:21-27, Suppl 9, 1996.
215. Santen, R.J. Long term tamoxifen therapy: Can an antagonist become an agonist? (editorial) J. Clin Endocrinol. Metab. 81:2027-2029, 1997.
216. Santner, S.J., Pauley, R.J., Tait, L., Kaseta, J., Santen R.J. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J. Clin. Endocrinol. Metab. 82:200-208, 1997.
217. Masamura, S., Santner, S.J., Gimotty, P., George, J., Santen, R.J. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake. Br. Cancer Res. Treat. 42:215-226, 1997.
218. Santen, R.J., Thibault, A., Myers, C., Chung, L. Meeting summary: Workshop conference on endocrine therapy of advanced prostate cancer, Airlie House, November 3-4, 1996, Urol Oncol 3:31-38, 1997.
219. Santen, R.J., Santner, S.J, Pauley, R.J., Tait, L., Kaseta, J., Demers, L.M., Hamilton, C., Yue, W. and Wang J.-P. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?, J. Steroid Biochem. Mol. Biol., 61:267-271, 1997.
220. Sinha, S, Kaseta J., Santner, S.J., Demers, L.M., Bremner, W.J. and Santen, R.J. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat, Breast Cancer Research and Treatment, 48:45-51, 1998.
221. Yue, W., Wang, J.-P., Hamilton, C.J., Demers, L.M., and Santen, R.J. *In Situ* aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Research, 58:927-932. 1998.
222. Mor, G., Yue, W., Santen, R.J., Gutierrez, L., Eliza, M., Berstein, L., Harada, N., Wang J., Lysiak, J., Diano, S., Naftolin, F. Macrophages, estrogen and the microenvironment of breast cancer. Journal Steroid Biochemistry and Molecular Biology. 67:403-11, 1998.
223. Santen, R.J., Martel, J., Hoagland, M., Naftolin, F., Roa, L., Harada, N., Hafer, L., Zaino, R., Pauley, R., and Santner, S. Demonstration of aromatase activity and its regulation in breast

- tumor and benign breast fibroblasts. Breast Cancer Research and Treatment, 49:S93-S99, 1998.
224. Santner, S.J., Albertson, B., Zhang, G-Y., Zhan G-H., Santulli, M, Wang, C., Demers, L.M., Shackleton, C., Santen, R.J. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. Journal of Clinical Endocrinology and Metabolism, 83:2104-2109, 1998.
225. Jeng, M-H., Shupnik, M.A., Bender, T.P., Bandyopadhyay, D., Kumar, R., Masamura, S., and Santen, R.J. Estrogen receptor expression and function in long term estrogen deprived human breast cancer cells. Endocrinology, 139:4164-4174, 1998.
226. Yue, W., Santner, S.J., Masamura, S., Wang, J-P., Demers, L.M., Hamilton, C., Santen, R.J. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Research and Treatment, 49:S1-S7, 1998.
227. Santen, R.J. written for the Organizing Committee. Consensus Statement: Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 83:1993-1999, 1998.
228. Santen, R.J., Pritchard, K., Burger, H. The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer. Obstetrical and Gynecological Survey 53:S1-S83, 1998.
229. Santen, R.J. written for the Organizing Committee. Consensus statement: treatment of estrogen deficiency symptoms in women surviving breast cancer. Climacteric, 1:148-158, 1998.
230. Costa, L., Kopreski, M., Demers, L., Chinchilli, V., Santen, R., Harvey, H., and Lipton, A. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast cancer. Cancer, 85:100-103, 1999.
231. Santen, R.J., Yue, W., Naftolin, F., Mor, G., Berstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocrine-Related Cancer, 6:235-243, 1999.
232. Yue, W., Santen, R.J., Wang, J-P., Hamilton, C.J., Demers, L.M. Aromatase within the breast. Endocrine-Related Cancer 6:157-164, 1999.
233. Santen, R.J. and Petroni, G. Relative versus attributable risk of breast cancer from estrogen replacement therapy. Journal of Clinical Endocrinology and Metabolism, 84:1875-1881, 1999.
234. Santen, R.J. and Harvey, H.A. Use of aromatase inhibitors in breast carcinoma. Endocrine-Related Cancer 6:75-92, 1999.
235. Swain, S., Santen, R.J., Burger, H., and Pritchard, K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 1 Oncology 13:109-136, 1999.
236. Swain, S., Santen, R.J., Burger, H., and Pritchard, K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2 Oncology 13:245-267, 1999.
237. Swain, S., Santen, R.J., Burger, H., and Pritchard, K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 3 Oncology 13:397-432, 1999.
238. Pinkerton, J.V., Santen, R.J. Alternatives to the use of estrogen in post-menopausal women. Endocrine Reviews, 20:308-320, 1999.

239. Shim, W.S., DiRenzo, J., DeCaprio, J.A, Santen, R. J., Brown, M., Jeng, M-H. Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium. Proceedings of the National Academy of Sciences of the United States of America. 96:208-13, 1999.
240. Swain, S., Santen, R.J., Burger, H., and Pritchard, K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4 Oncology 13:551-575, 1999.
241. Swain, S., Santen, R.J., Burger, H., and Pritchard, K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 5 Oncology 13:721-735, 1999.
242. Swain, S., Santen, R.J., Burger, H., and Pritchard, K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6 Oncology 13:859-875, 1999.
243. Santen, R.J. and Pinkerton, J.V. Alternatives to the use of estrogen in post-menopausal women. Menopausal Medicine, 7:1-7, 1999.
244. Berstein, L.M., Larinonov, A.A., Pauley, R.J., et al. Aromatase gene expression and its modifying factors in breast tumor tissue. Voprosy Onkologii 45:504-510, 1999.
245. Santen, R.J. and Harvey, H.A. Use of aromatase inhibitors in breast carcinoma. Women and Cancer, 2:121-134, 2000.
246. Pinkerton, J.V., Barrett, J.R., Ropka, M.E., Clayton, A.L., Santen, R.J. Decision making about hormone replacement therapy: need for risk assessment questionnaire. Obstetrics & Gynecology 95:S18, 2000.
247. Pauley, R.J., Santner, S.J., Tait, L.R., Bright, R.K., and Santen, R.J. Regulated CYP19 aromatase transcription in breast stromal fibroblasts. Journal of Clinical Endocrinology & Metabolism 85:837-846, 2000.
248. Shim, W-S., Conaway, M., Masamura, S., Yue, W., Wang, J-P, and Santen, R.J. Estradiol hypersensitivity and mitrogen-activated protein kinase expression in long term estrogen deprived human breast cancer cells *in vivo*. Endocrinology 141:396-405, 2000.
249. Jeng, M-H., Yue, W., Eischeid, A., Wang, J-P., and Santen, R.J. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 62:167-175, 2000.
250. Jefcoate, C.R., Liehr, J.G., Santen, R.J., Sutter, T.R., Yager, J., Yue, W., Santner, S., Tekmal, R., Demers, L., Pauley, R., Mor, G., Berstein, L. Tissue-specific synthesis and oxidative metabolism of estrogens. Journal of the National Cancer Institute. Monograph No. 27, Oxford University Press, pp. 95-112, 2000.
251. Santen, R.J. Symposium Overview. Journal of the National Cancer Institute. Monograph 27., Oxford University Press, pp. 15-16, 2000.
252. Haden K. Santen R. Breast cancer prevention with tamoxifen. Lippincott's Primary Care Practice 4:434-40, 2000.
253. Santen, R.J., Petroni, G., Pinkerton, J.V. and McCartney, C. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism, 86:16-23, 2001.

254. Song, R.X., Mor, G., Naftolin, F., McPherson, R.A., Song, J., Zhang, Z., Yue, W., Wang, J-P., Santen, R.J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 β -estradiol. Journal of the National Cancer Institute, 93:1714-1723, 2001.
255. Santen, R.J. The potential of aromatase inhibitors in breast cancer prevention. Voprosy Onkologii (Problems of Oncology), 47:187-194, 2001.
256. Santen, R.J., Petroni, G.R., Fisch, M.J., Myers, C.E., Theodorescu, D., Cohen, R.B. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer, 92:2095-101, 2001.
257. Devanesan, P., Santen, R.J., Bocchinfuso, W.P., Korach, K.S., Rogan, E.G., Cavalieri, E. Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. Carcinogenesis 22:1573-6, 2001.
258. Pinkerton, J.V., Santen, R.J. Use of alternatives to estrogen for treatment of menopause. Minerva Endocrinol. 27:21-41, 2002.
259. Santen, R.J., Jeng, M-H., Wang, J-P, Song, R.X., Masamura, S., McPherson, R., Santner, S., Yue, W., Shim, W-S. Adaptive hypersensitivity to estradiol: potential mechanism for hormonal responses in breast cancer patients. The Journal of Steroid Biochemistry & Molecular Biology 79:115-125, 2001.
260. Yue W. Bernstein LM. Wang JP. Clark GM. Hamilton CJ. Demers LM. Santen RJ. The potential role of estrogen in aromatase regulation in the breast. Journal of Steroid Biochemistry & Molecular Biology 79:157-64, 2001.
261. Santen RJ. Pinkerton J. McCartney C. Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. Journal of Clinical Endocrinology & Metabolism. 86:16-23, 2001.
262. Song, R.X., McPherson, R.A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., and Santen, R.J. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc pathway activation. Molecular Endocrinology 16:116-127, 2002.
263. Santen, R.J., Song, R.X., McPherson, R., Kumar, R., Adam, L., Jeng, M.H., Yue, W. The role of mitogen-activated protein (MAP) kinase in breast cancer. The Journal of Steroid Biochemistry & Molecular Biology 80:239-256, 2002.
264. Zhang, Z., Maier, B., Santen, R.J. and Song, R.X-D. Membrane association of estrogen receptor α mediates estrogen effect on MAPK activation. Biochemical Biophysical Research Communications 294:926-33, 2002.
265. Santen, R.J., Pinkerton, J.V., Conaway, M., Ropka, M., Wisniewski, L., Demers, L., and Klein, K. Treatment of urogenital atrophy with low dose estradiol: preliminary results. Menopause. 9:179-187, 2002.
266. Santen, R.J. To block estrogen's synthesis or action: That is the question. The Journal of Clinical Endocrinology & Metabolism. 87:3007-3012, 2002.

267. Yue, W., Wang, J-P., Conaway, M., Masamura, S. and Santen, R.J. Activation of the MAP kinase pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143:3221-9, 2002.
268. Santen R.J. Pinkerton J.V. Conaway M. Ropka M. Wisniewski L. Demers L. Klein K.O. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 9:179-87, 2002.
269. Song R.X., Berstein L.M., Santen R.J. RESPONSE: Re: Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17beta-Estradiol and The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death. Journal of the National Cancer Institute. 94(15):1173-4, 2002.
270. Song R.X., Santen, R.J., Kumar, R., Adam, L., Jeng, M-H, Masamura, S., Yue, W. Adaptive mechanisms induced by long term estrogen deprivation in breast cancer cells. Molecular and Cellular Endocrinology 193:29-42, 2002.
271. Fitzpatrick, L. A. and Santen, R.J. Hot flashes: The old and the new, what is really true? Mayo Clinic Proceedings, 77:1207-18, 2002.
272. Berstein, L.M. and Santen, R.J. Molecular mechanisms of resistance to tamoxifen. Voprosy Onkologii 48:17-23, 2002.
273. Song, R. X-D. and Santen, R.J. Apoptotic action of estrogen. Apoptosis 8:55-60, 2003.
274. Berstein, L.M., Yue, W., Wang, J.P., Lykkesfeldt, A., Naftolin, F., Harada, N., Shanabrough, M., Santen, R.J. New approaches to the understanding of tamoxifen action and resistance. Endocrine Related Cancer 10:267-277, 2003.
275. Santen, R.J., Song, R.X., Zhang, Z., Kumar, R., Jeng, M-H., Masamura, S., Yue, W., Berstein, L. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over SERMs for breast cancer treatment and prevention. Endocrine-Related Cancer 10:111-130, 2003.
276. Santen, R.J. and Terakawa, N. Forward in Special issue: International congress on hormonal steroids and hormones and cancer. Endocrine-Related Cancer 10:109-110, 2003.
277. Santen, R.J. Inhibition of aromatase: insights from recent studies. Steroids 68:559-567. 2003.
278. Yue, W., Santen, R.J., Wang, J-P., Li, Y., Verderame, M.F., Bocchinfuso, W.P., Korach, K.S., Devanesan, P., Todorovic, R., Rogan, E.G., and Cavalieri, E.L. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. Journal of Steroid Biochemistry and Molecular Biology 86:477-486, 2003
279. Sasano, H., Edwards, D.P., Anderson, T.J., Silverberg, S.G., Evans, D.B., Santen, R.J., Ramage, P., Simpson, E.R., Bhatnagar, A.S., and Miller, W.R. Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. Journal of Steroid Biochemistry & Molecular Biology, 86:239-244, 2003.
280. Yue, W., Wang, J-P., Conaway, M.R., Li, Y., and Santen, R.J. Adaptive hypersensitivity

following long-term estrogen deprivation: involvement of multiple signal pathways. Journal of Steroid Biochemistry and Molecular Biology, 86:265-274, 2003.

281. Santen, R.J. Risk of breast cancer with progestins: Critical assessment of current data. Steroids, 68:953-964, 2003.
282. Mishra, S.K., Mzumdar, a., Vadlamudi, R.K., Li, F., Wang, R-A., Yu, W., Jordan, V.C., Santen, R.J. and Kumar, R. MICOA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor- α transactivation functions. The Journal of Biological Chemistry, 278:19209-19219, 2003.
283. Santen, R.J. Risk of breast cancer with hormone therapy for menopausal women: critical assessment of existing data. Polish Journal of Endocrinology 55:312-321, 2004.
284. Santen, RJ, Song RX, Zhang Z., Kumar R, and Yue, W. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clinical Cancer Research, 10:337s-345s, 2004.
285. Berstein, L.M., Wang, J-P., Zheng, H., Yue, W., Conaway, M., and Santen, R.J. Long term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical Cancer Research, 10:1530-1534, 2004.
286. Song, R-X., Barnes, C.J., Zheng, Z., Bao, Y., Kumar, R., and Santen, R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proceedings of the National Academy of Medicine USA, 101:2076-2081, 2004.
287. McPherson, R.A., Conaway, M.C., Gregory, C.W., Yue, W., and Santen, R.J. The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate 58:325-334, 2004.
288. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart C. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer. Conference Summary Statement Clinical Cancer Research 10:327s-330s 2004.
289. Zhang, Z., Kumar, R., Santen, R.J., Song, X.-D. The role of adapter protein Shc in estrogen non-genomic action. Steroids 69:523-529, 2004.
290. Yue, W., Wang, J-P., Bocchinfuso, W., Korach, K., Devanesan, P., Rogan, E., Cavalieri, E., and Santen, R.J. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clinical Cancer Research 11:925s-930s, 2005.
291. Santen, R.J., Song, R.X., Zhang, Z., Kumar, R., Jeng, M.H., Masamura, S., Lawrence, J., MacMahon, L.P., Yue, W. and Berstein, L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. Journal of Steroid Biochemistry & Molecular Biology 95:155-65, 2005.
292. Wang, S., Paris, F., Song, R.X., Demers, L., Sultan, C., Sundarum, B., Settlege, J., Ohorodnik, S. and Santen, R.J. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. Journal of Clinical Endocrinology & Metabolism 90:1407-13, 2005.

293. Santen, R.J., Mansel, R. Benign breast disorders. New England Journal of Medicine 353:275-85, 2005.
294. Sasano, H., Anderson, T.J., Silverberg, S.G., Santen, R.J., Conway, M., Edwards, D.P., Krause, A., Bhatnagar, A.S., Evans, D.B., Miller, W.R. The validation of new aromatase monoclonal antibodies for immunohistochemistry – A correlation with biochemical activities in 46 cases of breast cancer. The Journal of Steroid Biochemistry & Molecular Biology 95:35-39, 2005.
295. Song RX. Zhang Z. Mor G. Santen RJ. Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER (+) breast cancer cells. Apoptosis 10(3):667-78, 2005.
296. Come SE. Buzdar AU. Ingle JN. Arteaga CL. Brodie AM. Colditz GA. Johnston SR. Kristensen VN. Lonning PE. McDonnell DP. Osborne CK. Russo J. Santen RJ. Yee D. Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clinical Cancer Research 11(2 Pt 2):861s-4s, 2005.
297. Santen, R.J., Song, R.X., Zhang, Z., Kumar, R., Jeng, M-H., Masamura, S., Lawrence, J. Jr., Berstein, L., Yue, W. Long term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocrine-Related Cancer 12 Suppl 1:S61-73, 2005.
298. Sasano, H., Anderson, T.J., Silverberg, S.G., Santen, R.J., Conway, M., Edwards, D.P., Krause, A., Bhatnagar, A.S., Evans, D.B., Miller, W.R. The validation of new aromatase monoclonal antibodies for immunohistochemistry—a correlation with biochemical activities in 46 cases of breast cancer. Journal of Steroid Biochemistry & Molecular Biology 95:35-9, 2005.
299. Song, R.X-D., Zhang, Z., Santen, R.J. Estrogen rapid action via protein complex formation involving ER α and Src. Trends in Endocrinology and Metabolism 16:347-53, 2005.
300. Gee J.M., Howell, A., Gullick, W.J., Benz, C.C., Sutherland, R.L., Santen, R.J., Martin, L.A., Ciardiello, F., Miller, W.R., Dowsett, M., Barrett-Lee, P., Robertson, J.F., Johnston, S.R., Jones, H.E., Wakeling, A.E., Duncan, R., Nicholson, R.I. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signaling pathways and implications for future treatment. Endocrine-Related Cancer 12 Suppl 1:S1-7, 2005.
301. McMahon LP. Yue W. Santen RJ. Lawrence JC Jr. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Molecular Endocrinology. 19:175-83, 2005.
302. Yue, W., Wang, J-P., Li, Y., Fan, P., Santen, R.J. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. International Journal of Cancer 117:746-754, 2005.
303. Santen, R.J., Lobenhofer, E.K., Afshari, C.A., Bao, Y., Song, R.X. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Research and Treatment 94:213-23, 2005.

304. Yaffe, M., Hendrix, S., Pike, M., Santen, R., Eden, J., Genazzani, A. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer? Gynecological Endocrinology 21 (suppl 1):17-21, 2005.
305. Santen, R. Menopausal hormone therapies: their effect on mammographic density and breast cancer risk. Gynecological Endocrinology 21 (suppl 1):12-16, 2005.
306. Santen, R.J., Lynch, A.R., Neal, L.R., and McPherson, R.A., Yue, W. Farnesyl-thiosalicylic acid (FTS): Inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Anti-Cancer Drugs 17:33-40, 2006
307. Smith, I., Dowsett, M., Yap, Y-S., Walsh, G., Lonning, P.E., Santen, R.J., Hayes, D. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Journal of Clinical Oncology 24:2444-7, 2006
308. Song, R-X., Fan, P., Yue, W., Chen, Y. and Santen, R.J. Role of receptor complexes in the extra-nuclear actions of ER α in breast cancer. Endocrine Related Cancer 13 Suppl 1:S3-S13, 2006.
309. Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., Muti, P., Rogan E., Russo, J., Santen, R., Sutter, T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochimica et Biophysica Acta 1766:63-78, 2006.
310. Song RX and Santen, R.J. Membrane-initiated estrogen signaling in breast cancer. Biology of Reproduction 75:9-16, 2006.
311. Howell, A., Clarke, R.B., Evans, G., Bundred, N., Cuzick, J., Santen, R., Allred, C. Estrogen deprivation for breast cancer prevention. Recent Results in Cancer Research 174:151-167, 2007.
312. Fan, P., Wang, J-P., Santen, R.J., Yue, W. Long term treatment with tamoxifen facilitates translocation of ER α out of the nucleus and enhances its interaction with epidermal growth factor receptor in MCF-7 breast cancer cells. Cancer Research 67:1352-60, 2007.
313. Santen, R.J., Demers, L., Ohorodnik, S., Settladge, J., Langecker, P., Blanchett, D., Wang, S. Superiority of gas chromatography/ tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72:666-671, 2007.
314. Santen, R.J. and Allred, D.C. The estrogen paradox. Nature Clinical Practice 3:496-497, 2007.
315. Santen, R. J. The oestrogen paradox: a hypothesis. Polish Journal of Endocrinology 58:222-227, 2007.
316. Park, H-Y., Aiyar, S.E., Fan, P., Wang, J., Yue, W., Okouneva, T., Cox, C., Jordan, M.A., Demers, L., Cho, H., Kim, S-H., Song, R.X-D., Santen, R.J. Effects of tetramethoxystilbene (TMS) on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Research 67:5717-26, 2007.

317. Stanczyk, F.Z., Lee, J., Santen, R.J. Standardization of Steroid Hormone Assays: Why, How and When? Cancer Epidemiol Biomarkers Prev 16:1713-1719, 2007.
318. The Breast Cancer Prevention Collaborative Group: Santen,R.J., Boyd, N. F., Chlebowski, R.T., Cummings, S., Cuzick, J.F., Dowsett, M., Easton, D., Forbes, J.F., Key, T., Hankinson, S.E., Howell, A., and Ingle, J. Critical assessment of new risk factors for breast cancer: considerations for developing an improved risk prediction model. Endocrine-Related Cancer 14:169-87, 2007.
319. Song, X-D., Zhang, Z., Chen, Y., Bao, Y., Santen, R.J. Estrogen signaling via a linear pathway involving insulin-like growth factor I Receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148:4091-101, 2007.
320. Sogon, T., Masamura, S., Hayashi, S., Santen, R.J., Nakachi, K., Eguchi, H. Demethylation of promoter C region of estrogen receptor α gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells. Journal of Steroid Biochemistry and Molecular Biology 105(1-5):106-14, 2007.
321. Harvey JA, Santen RJ, Petroni GR, Bovbjerg VE, Smolkin ME, Sheriff FS, Russo J. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, ER, PgR, and proliferation indices. Menopause 15:67-73, 2008.
322. Harvey, J.A., Santen, R.J., Petroni, G.R., Bovbjerg, V.E., Smolkin, M.E., Sheriff, F.S., Russo, J. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, ER, PgR, and proliferation indices. Menopause 15:67-73, 2008.
323. Santen, R.J. The oestrogen paradox: an hypothesis. Breast Cancer Research 9(Suppl 2):S21, 2007.
324. Santen, R.J. Introduction: Challenging Established Dogma. Breast Cancer Research 9(Suppl 2):S16, 2007.
325. Yue W. Fan P. Wang J. Li Y. Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. Journal of Steroid Biochemistry & Molecular Biology 106:102-10, 2007.
326. Rahman, M., Lax, S.F., Sutter, C.H., Tran, Q.T., Stevens, G.L., Emmert, G.L., Russo, J., Santen, R.J., Sutter T.R. CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. Drug Metabolism and Disposition 36:963-70, 2008.
327. Santen, R.J. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Women's Health 4:207-210, 2008.
328. Santen, R.J. Assessing individual risk for breast cancer: role of oestrogens and androgens. Breast Cancer Research 10(Suppl 4):S10, 2008.

329. Santen, R.J., Lee, J.S., Wang, S., Demers, L.M., Mauras, N., Wang, H., Singh, R. Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids 73:1318-21, 2008.
330. Liu, G.J., Wu, Y.S., Brenin, D., Yue, W., Aiyar, S., Gompel, A., Wang, J.P., Tekmal, R.R., Santen, R.J. Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. Breast Cancer Research and Treatment 111:343-51, 2008.
331. Santen, R.J., Song, R.X., Masamura, S., Yue, W., Fan, P., Sogon, T., Hayashi, S., Nakachi, K., Eguchi, H. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Advances in Experimental Medicine and Biology 630:19-34, 2008.
332. Santen, R., Cavalieri, E., Rogan, E., Russo, J., Guttenplan, J., Ingle, J., Yue, W. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent genotoxic effects. Steroid Enzymes and Cancer: Annals of the New York Academy of Sciences 1155:132-140, 2009.
333. Santen, R.J., Fan, P., Zhang, Z., Bao, Y., Song, R.X-D., Yue, W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and –resistant breast cancer cells. Steroids 74:586-594, 2009.
334. Fowler, A.M., Santen, R.J., Allred, D.C. “Dwarf” estrogen receptor in breast cancer and resistance to tamoxifen. Journal of Clinical Oncology 27(21):3413-5, 2009.
335. Santen, R.J., Brodie, H., Simpson, E.R., Siiteri, P.K., Brodie, A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocrine Reviews 30:343-75, 2009.
336. Fan, P., Yue, W., Wang, J.P., Aiyar, S., Li, Y., Kim, T.H., Santen, R.J. Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. Endocrinology 150:2036-45, 2009.
337. Song, R.X., Chen, Y., Zhang, Z., Bao, Y., Yue, W., Wang, J.P., Fan, P., Santen R.J. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. Journal of Steroid Biochemistry & Molecular Biology 118(4-5):219-30, 2010.
338. Yue, W., Wang, J-P., Li, Y., Fan, P., Liu, G., Zhang, N., Conaway, M., Wang, H., Korach, K.S., Bocchinfuso, W., Santen, R. Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. International Journal of Cancer 127:1748-1757, 2010.
339. Vachon, C., Sasano, H., Ghosh, K., Brandt, K., Watson, D., Lingle, W., Goss, P., Reynolds, C., Li, R., Aiyar, S.E., Pankratz, V.S., Santen, R.J., Ingle, J.N. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Research and Treatment 125:243-252, 2011.
340. Aiyar, S.E., Park, H., Aldo, P.B., Mor, G., Gildea, J.J., Miller, A.L., Thompson, E.B., Castle, J.D., Kim, S., Santen, R.J. TMS, a chemically modified herbal derivative of resveratrol, induces cell death by targeting Bax. Breast Cancer Research and Treatment 124:265-277, 2010.

341. Santen, R.J., Allred, D.C., Ardoin, S.P., Archer, D.F., Boyd, N., Braunstein, G.D., Burger, H.G., Colditz, G.A., Davis, S.R., Gambacciani, M., Gower, B.A., Henderson, V.W., Jarjour, W.N., Karas, R.H., Kleerekoper, M., Lobo, R.A., Manson, J.E., Marsden, J., Martin, K.A., Martin, L., Pinkerton, J.V., Rubinow, D.R., Teede, H., Thiboutot, D.M., Utian, W.H. Postmenopausal hormone therapy: an Endocrine Society scientific statement. Journal of Clinical Endocrinology and Metabolism 95(7 Suppl 1):s1-s66, 2010.
342. Li, Y., Wang, J.P., Santen, R.J., Kim, T.H., Park, H., Fan, P., Yue, W. Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology 151:5146-5156, 2010.
343. Santen, R.J. Clinical review: Effect of endocrine therapies on bone in breast cancer patients. Journal of Clinical Endocrinology and Metabolism 96:308-319, 2011.
344. Kim, T., Park, H., Yue, W., Wang, J.P., Atkins, K.A., Zhang, Z., Rogan, E.G., Cavaliere, E.L., Mohammad, K.S., Kim, S., Santen, R.J., Aiyar, S.E. Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland. Breast Cancer Research and Treatment 126:779-789, 2011.
345. Taboada, M., Santen, R., Lima, J., Hossain, J., Singh, R., Klein, K.O., Mauras, N. Pharmacokinetics and pharmacodynamics of oral and transdermal 17 β estradiol in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 96(11):3502-10, 2011.
346. Berstein, L.M., Yue, W., Wang, J.P., Santen, R.J. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Research and Treatment 128:109-117, 2011.
347. Mauras, N., Torres-Santiago, L., Taboada, M., Santen, R. Estrogen therapy in Turner syndrome: does the type, dose and mode of delivery matter? Pediatric Endocrine Reviews.
348. Gompel, A., Santen, R.J. Hormone therapy and breast cancer risk 10 years after the WHI [Review]. Climacteric 15(3):241-249, 2012.
349. Yager, James D., Santen, Richard J. Mechanisms relating estrogens to breast cancer. Translational Endocrinology and Metabolism 3(1):75-93, 2012.
350. Santen, R.J. Memorial Pentti Siiteri. Journal of Steroid Biochemistry and Molecular Biology 2012, in press.
351. Eggleston, E., Liu, Z., Mirmira, R.G., Silva, C.M., Shu, J., Santen, R.J. Insights into mentorship for endocrinologists. Journal of Clinical Endocrinology and Metabolism 97(11):3891-3896, 2012. 354.
352. Santen, R.J., Yue, W., Heitjan, D.F. Occult breast tumor reservoir: biological properties and clinical significance. Hormones and Cancer 4(4):195-207 (2013).
353. Torres-Santiago, L., Mericq, V., Taboada, M., Unanue, N., Oerter-Klein, K., Singh, R., Hossain, J., Santen, R., Ross, J.L., Mauras, N. Metabolic effects of oral versus transdermal 17 β -estradiol (E₂): a randomized clinical trial in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 98(7):2716-2724, 2013.

354. Santen, R.J, Song, Y., Yue, W., Wang, J-P., Hietjan, D. Effects of menopausal hormonal therapy on occult breast tumors. The Journal of Steroid Biochemistry and Molecular Biology, 137:150-156 (2013).
355. Santen, R.J. Menopausal hormone therapy and breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology 142:52-61, 2014.
356. Yue, W., Wang, J-P., Zhang, L., Wang, W., Santen, R.J., Aiyar, S.E. Induction of apoptosis in human refractory breast cancer: horizontal modulation is superior to vertical. Journal of Experimental Therapeutics and Oncology 10(3):165-168, 2013.
357. Gompel, A., Baber, R.J., de Villiers, T.J., Huang, K.E., Santen, R.J., Shah, D., Villaseca, P., Shapiro, S. Oncology in midlife and beyond. Climacteric 16(5):522-535 (2013).
358. Yue, W., Yager, J.D., Wang, J.P., Jupe, E.R., Santen, R.J. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. [Review]. Steroids 78(2):161-170 (2013).
359. Santen, R.J., Kagan, R., Altomare, C.J., Komm, B., Mirkin, S., Taylor, H.S. Current and evolving approaches to individualizing estrogen receptor-based therapy approaches for menopausal women. Journal of Clinical Endocrinology and Metabolism 99(3):733-747, 2014
360. Yue, W., Wang, J-P., Zhang, L., Wang, W., Santen, R.J., Aiyar, S.E. Induction of apoptosis in human refractory breast cancer: horizontal modulation is superior to vertical. Journal of Experimental Therapeutics and Oncology 10(3):165-168, 2013.
361. Santen R.J. Yue W. Hietjan D.F Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiology, Biomarkers & Prevention 21(7):1038-48, 2012.
362. Hartmann, L.C., Radisky, D.C., Frost, M.H., Santen, R.J., Vierkant, R.A., Benetti, L.L., Tarabishy, Y., Ghosh, K., Visscher, D.W., Degnim, A.C. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prevention Research 7(2):211-217, 2014.
363. Pathiraja, T.N., Nayak, S.R., Xi, Y., Jiang, S., Garee, J.P., Edwards, D.P., Lee, A.V., Chen, J., Shea, M.J., Santen, R.J., Gannan, F., Kangaspeska, S., Jelinek, J., Issa, J-P., Richer, J.K., Elias, A., McIlroy, M., Young, L.S., Davidson, N.E., Schiff, R., Li, W., Oesterreich, S. Epigenetic reprogramming of HOXC10 in endocrine resistant breast cancer. Science Translational Medicine 6:229, 2014.
364. Santen, R.J., Stuenkel, C.A., Burger, H.G., Manson, J.E. Competency in menopause management: whither goest the internist? Journal of Women's Health 23(4):1-5, 2014.
365. Smith, C.L., Santen, R.J., Komm, B., Mirkin, S. Breast-related effects of selective estrogen receptor modulators and tissue selective estrogen complexes. Breast Cancer Research 16:212-226, 2014.
366. Santen, R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 17:1-14, 2014.

367. Santen, R.J. Menopausal hormone therapy and breast cancer. Journal of Steroid Biochemistry and Molecular Biology 142:52-61, 2014.
368. Hartmann, L.C., Degnim, A.C., Santen, R.J., Dupont, W.D., Khosh, K. Atypical hyperplasia of the breast – risk assessment and management options. New England Journal of Medicine 372:78-89, 2015.
369. Geffner, M.E., Santen, R., Kopchick, J. Editor's Choice - Comments on Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology March 10, 2015.
370. Chen, H., Wang, J-P., Santen, R.J., Yue, W. Adenosine monophosphate activated protein kinase (AMPK), a mediator of estradiol-induced apoptosis in long-term estrogen deprived breast cancer cells. Published online February 27, 2015.
371. Mauras, N., Santen, R.J., Colon-Otero, G., Hossain, J., Wang, Q., Mesaros, C., Blair, I.A. Estrogens and their genotoxic metabolites are increased in obese prepubertal girls. Journal of Clinical Endocrinology and Metabolism, Epub ahead of print, 2015.
372. Santen, R.J., Demers, L.M., Ziegler, R.G. Workshop on measuring estrogen exposure and metabolism: Summary of the presentations. Steroids 99:1-7, 2015.
373. Demers, L.M., Hankinson, S.E., Haymond, S., Key, T., Rosner, W., Santen, R.J., Stanczyk, F. Z., Vesper, H.W., Ziegler, R.G. Measuring estrogen exposure and metabolism: workshop recommendations on clinical issues. Journal of Clinical Endocrinology and Metabolism. Published online April 7, 2015.
374. Stuenkel, C.A., Davis, S.R., Gompel, A., Lumsden, M.A., Murad, M.H., Pinkerton, J.V., Santen, R.J. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 100:3975-4011, 2015.
375. Gurka, M.J., Vishnu, A., Santen, R.J., DeBoer, M.D. Progression of metabolic syndrome severity during the menopausal transition. Journal of the American Heart Association 5(8), 2016.
376. Santen, R.J., Joham, A., Fishbein, L., Vella, K.R., Ebeling, P.R., Gibson-Helm, M., Teede, H. Career advancement: Meeting the challenges confronting the next generation of endocrinologists and endocrine researchers. Journal of Clinical Endocrinology and Metabolism 101:4512-4520, 2016.
377. Stuenkel, C.A., Santen, R.J. An introduction to the Endocrine Society Clinical Practice Guideline on treatment of symptoms of the menopause. Post Reproduction Health 22:6-8, 2016.
378. Campbell, S.T., Santen, R.J., Bruns, D.E. Undetectable urine calcium in a gastric bypass patient. Clinical Chemistry 62:1161, 2016.
379. Santen, R.J., Song, Y., Wang, J.P., Yue, W. Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene (review). Journal of Steroid Biochemistry & Molecular Biology 170:61-64, 2017.

380. Santen, R.J., Radisky, D.C., Degnim, A., Frost, M.H., Vachon, C.M., Ghosh, K., Guestini, F., McNamara, K.M., Sasano, H. Aromatase expression in atypical ductal hyperplasia in women. Breast Cancer Research & Treatment 163:623-629, 2017.
381. Santen, R.J., Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. Menopause 24:589-595, 2017.
382. Santen, R.J., Barrett, E.J., Siragy, H.M., Farhi, L.S., Fishbein, L., Carey, R.M. The jewel in the crown: specific aims section of investigator-initiated grant proposals. Journal of the Endocrine Society 1:1194-1202, 2017.
383. Santen, R.J., Stuenkel, C.A., Davis, S.R., Pinkerton, J.V., Gompel, A., Lumsden, M.A. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. Online, <https://doi.org/10.1210/JC2017-01138>.
384. Schnatz, P.F., Pinkerton, J.V., Utian, W.H., Appt, S.E., de Villiers, T.J., Henderson, V.W., Hodis, H.N., Kaunitz, A.M., Maki, P.M., Manson, J.E., McClung, M.R., Richard-Davis, G., Santen, R.J., Santoro, N.F., Sarrel, P.M., Shifren, J.L., Simon, J.A., Stuenkel, C.A., Taylor, M. Menopause 2017, Highlights of North American Menopause Translational Meeting. The Journal of the North American Menopause Society 24 (11):1221-1235, 2017.
385. Klein, K.O., Rosenfield, R., Santen, R.J., Gawlik, A., Backeljauw, P., Gravholt, C.H., Sas, T., Mauras, N. Estrogen replacement in Turner syndrome: literature review and practical considerations. Journal of Clinical Endocrinology and Metabolism 103(5):1790-1803, 2018.
386. Yue, W., Wang, J., Atkins, K.A., Bottalico, L., Mesaros, C., Blair, I.A., Santen, R.J. Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen. International Journal of Cancer 143:1259-1268, 2018.
387. Santen, R.J., Jewell, C.M., Yue, W., Heitjan, D.F., Raff, H., Katen, K.S., Cidlowski, J.A. Glucocorticoid receptor mutations and hypersensitivity to endogenous and exogenous glucocorticoids. Journal of Clinical Endocrinology and Metabolism 103(10):3630-3639, 2018.
388. Santen, R.J., Yue, W. Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study. Climacteric, Nov 1:1-10, 2018.
389. Mauras, N., Torres-Santiago, L., Santen, R., Mericq, V., Ross, J., Colon-Otero, G., Damaso, L., Hossain, J., Wang, Q., Mesaros, C., Blair, I.A. Impact of route of administration on genotoxic estrogens concentrations using oral vs. transdermal estradiol in girls with Turner Syndrome. Clinical Endocrinology, 2018, in press.
390. Yue, W., Verhoeven, C., Bernnink, H.C., Wang, Ji-Ping, Santen, R.J. Pro-apoptotic effects of estetrol on long-term estrogen-deprived breast cancer cells and at low doses on hormone-sensitive cells. Breast Cancer: Basic and Clinical Research 13:1-8, 2019.
391. Santen, Richard J. "Re-booting" after retirement: novel approach using telemedicine to solve the work-force gap in diabetes management. Maturitas, in press, 2020.

392. Santen, R.J., Heitjan, D.F., Gompel, A., Lumsden, M.A., Pinkerton, J. V., Davis, S.R., Stuenkel, C.A. Underlying breast cancer risk and menopausal hormone therapy. Journal of Clinical Endocrinology and Metabolism, in press, 2020.

393. Marsden J, British Menopause Society. British Menopause Society consensus statement: The risks and benefits of HRT before and after a breast cancer diagnosis. Post Reprod Health. 2019;25(1):33-37. doi:10.1177/2053369119825716.

Chapters

1. Bardin, C.W., Santen, R.J. Androgen assay in blood and other biological fluids. IN: Steroid Hormones, R. I. Dorfman (ed), North-Holland Publishing Co., Amsterdam; American Elsevier Publishing Co., New York, pp. 53-70, 1975.
2. Santen, R.M. Evaluation of testicular and ovarian disorders. IN: Radioassay: Clinical Concepts, Proc. Symp. on Radioimmunoassay, Washington, D.C., pp. 145-153, 1974.
3. Baker, H.W.G., Bardin, C.W., Eichner, G.J., Jefferson, L.S., Santen, R.J. Perfusion of the male reproductive tract: A model for the study of androgen secretion and action. IN: Hormonal Regulation of Spermatogenesis, F. French, et al. (ed), Plenum Publishing Corp., New York, pp. 135-144, 1975.
4. Kulin, H.E., Santen, R.J. Endocrinology of puberty in man. IN: Sixth Brook Lodge Workshop on Problems of Reproductive Biology: Regulatory Mechanisms of Male Reproductive Physiology, C.H. Spilman, et al. (ed), Excerpta Medica, Amsterdam, pp. 175-192, 1976.
5. Santen, R.J., Kulin, H.E. The male reproductive system. IN: Practice of Pediatrics, Vol. 1, Harper and Row Publishers Inc., Hagerstown, MD, chapter 53, pp. 1-44, 1976.
6. Chung, K.W., Blackburn, W.R., Bullock, L.P., Santen, R.J., Bardin, C.W. Leydig cell structure-function relationships in the mouse with xx sex reversal. IN: The Testis in Normal and Infertile Men, P. Troen and H.R. Nankin (ed), Raven Press, New York, pp. 45-55, 1977.
7. Baker, H.W.G., Worgul, T.J., Santen, R.J., Jefferson, L.S., Bardin, C.W. Effect of prolactin on nuclear androgens in perfused male accessory sex organs. IN: The Testis in Normal and Infertile Men, P. Troen and H.R. Nankin (ed), Raven Press, New York, pp. 379-385, 1977.
8. Bixler, E.O., Santen, R.J., Kales, A., Soldatos, C.R., Scharf, M.B. Inverse effects of thioridazine (Mellaril) on serum prolactin and testosterone concentrations in normal men. IN: The Testis in Normal and Infertile Men, P. Troen and H.R. Nankin (ed), Raven Press, New York, pp. 403-408, 1977.
9. Santen, R.J. Independent effects of testosterone and estradiol on the secretion of gonadotropins in man. IN: The Testis in Normal and Infertile Men, P. Troen and H.R. Nankin (ed), Raven Press, New York, pp.197-211, 1977.
10. Santen, R.J., Kulin, H.E. Evaluation of gonadotropins in man. IN: Techniques of Human Andrology, S. Hafez (ed), Elsevier, North-Holland Biomedical Press, pp. 251-263, 1977.
11. Santen, R.J. Clinical evaluation of infertile men. IN: Techniques of Human Andrology, S. Hafez (ed), Elsevier, North-Holland Biomedical Press, pp. 339-346, 1977.
12. Kulin, H.E., Santen, R.J. Disorders of sexual maturation in the female: Delayed adolescence and the variants of precocious puberty. IN: Endocrine Causes of Menstrual Disorders, J. Givens (ed), Year Book Medical Publishers Inc., pp. 53-85, 1978.
13. Musto, N.A., Santen, R.J., Huckins, C., Bardin, C.W. The H^{1c} rat: A model for late onset seminiferous tubule failure in man. IN: Animal Models for Research on Contraception and Fertility, N.J. Alexander (ed), Harper and Row Publishers, Hagerstown, MD, pp. 372-384, 1978.

14. Santen, R.J., Samojlik, E. Medical adrenalectomy for treatment of metastatic breast carcinoma. IN: Breast Cancer, W.L. McGuire (ed), Plenum Publishing Corp., New York, pp. 79-115, 1979.
15. Kulin, H.E., Santner, S.J., Santen, R.J., Murray, F.T., Hammond, J.M. The use of urinary gonadotropin measurements to evaluate the response to LHRH in hypogonadotropic states. IN: The LH-Releasing Hormone, C.G. Beling, A. Wentz (ed), Masson Publishing, New York, pp. 75-85, 1980.
16. Santen, R.J., Kulin, H.E. Hypogonadotropic hypogonadism and delayed puberty. IN: The Testis, H. Burger and D. de Kretser (ed), Raven Press, New York, pp. 329-356, 1981.
17. Santen, R.J. Independent control of LH secretion by testosterone and estradiol in the male. IN: Hormones in Normal and Abnormal Human Tissues, K. Fotherby and S.B. Pal (ed), Walter de Gruyter & Co., Berlin/New York, pp. 459-489, 1981.
18. Sharkey, F.E., Santen, R.J. Pathology of metastasis in human breast cancer. IN: Pharmanual: A Comprehensive Guide to the Therapeutic Use of Aminoglutethimide, R.J. Santen (ed), S. Karger AG, Basel/New York, pp. 1-46, 1981.
19. Santen, R.J., Samojlik, E. Aminoglutethimide: Part A. Pharmacology aspects. IN: Pharmanual: A Comprehensive Guide to the Therapeutic Use of Aminoglutethimide, R.J. Santen (ed), S. Karger AG, Basel/New York, pp. 101-124, 1981.
20. Santen, R.J., Worgul, T.J. Aminoglutethimide: Part B. Clinical aspects. IN: Pharmanual: A Comprehensive Guide to the Therapeutic Use of Aminoglutethimide, R.J. Santen (ed), S. Karger AG, Basel/New York, pp. 125-154, 1981.
21. Wells, Jr., S.A., Santen, R.J. The pituitary and adrenal glands. IN: Textbook of Surgery: The Biological Basis of Modern Surgical Practice, D.C. Sabiston (ed), W.B. Saunders Co., Philadelphia, pp. 737-792, 1981.
22. Santen, R.J., Brodie, A.M.H. Suppression of oestrogen production as treatment of breast carcinoma: Pharmacological and clinical studies with aromatase inhibitors. IN: Clinics in Oncology, Vol. 1, B.J.A. Furr (ed), W.B. Saunders Co. Ltd., England, pp. 77-130, 1982.
23. Kulin, H.E., Santen, R.J. Normal and aberrant pubertal development in man. IN: Comprehensive Reproductive Neuroendocrinology, J. Vaitukaitis (ed), Elsevier Biomedical, New York, p. 19-63, 1982.
24. Wells, S.A., Santen, R.J. Preservation of androgen secretion during suppression with aminoglutethimide. IN: Aminoglutethimide: Mechanism of Action and Clinical Results in Breast Cancer, F.J.A. Paesi (ed), CIBA-Geigy Ltd., Basel, pp. 59-71, 1982.
25. Santen, R.J., Kulin, H.E. The male reproductive system. IN: Practice of Pediatrics, Revised Ed., Vol. 7, V.C. Kelly (ed), Harper and Row, Philadelphia, chapter 37, pp. 1-48, 1983.
26. Page, R.B., Santen, R.J. Approach to the pituitary tumor: Anatomic, diagnostic and surgical considerations. IN: Diagnosis and Management of Endocrine-Related Tumors, R.J. Santen and A. Manni (ed), Martinus-Nijhoff Publishers, The Hague, pp. 1-44, 1984.

27. Santen, R.J., Warner, B., Demers, L.M., Dufau, M., Smith, J. Use of gonadotropin releasing hormone agonist analogs for treatment of human prostatic cancer. IN: LHRH and its Analogs - Contraceptive and Therapeutic Applications, B.H. Vickery, J.J. Nestor, Jr. and E.S.E. Hafez (ed), MTP Press, Lancaster-Boston, pp. 351-364, 1984.
28. Santen, R.J., Lipton, A., Harvey, H., Boucher, A.E., Henderson, C. Pharmacological mechanisms of oestrogen suppression with aminoglutethimide in women with breast cancer. IN: Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer, G.A. Nagel and R.J. Santen (ed), Hans Huber Publishers, Berne, pp. 38-57, 1984.
29. Harvey, H.A., Lipton, A., Santen, R.J. Clinical studies in advanced carcinoma. IN: Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer, G.A. Nagel and R.J. Santen (ed), Hans Huber Publishers, Berne, pp. 38-57, 1984.
30. Santen, R.J. The endocrinology of breast cancer. IN: Breast Cancer: Therapeutic Modalities Current and Future, H. Harvey, A. Lipton and M.A. Michalels (ed), Medical Education Services Ltd., Canada, pp. 81-89, 1984.
31. Lipton, A., Santen, R.J., Harvey, H.A. Aminoglutethimide clinical trials. IN: Breast Cancer: Therapeutic Modalities Current and Future, H. Harvey, A. Lipton and M.A. Michalels (ed), Medical Education Services Ltd., Canada, pp. 127-135, 1984.
32. Harvey, H.A., Lipton, A., Santen, R.J. Estrogen suppression in metastatic breast cancer. IN: Breast Cancer: Therapeutic Modalities Current and Future, H. Harvey, A. Lipton and M.A. Michalels (ed), Medical Education Services Ltd., Canada, pp. 159-162, 1984.
33. Santen, R.J., English, H.F., Warner, B.A. GnRH superagonist treatment of prostate cancer: Hormonal effects with and without an androgen biosynthesis inhibitor. IN: LHRH and its Analogues, Basic and Clinical Aspects, F. Labrie, A. Belanger and A. DuPont (ed), Excerpta Medica, Amsterdam, pp. 336-348, 1984.
34. Manni A., Santen, R.J. Endocrine treatment of breast cancer. IN: Current Therapy in Endocrinology and Metabolism, D.T. Krieger and C.W. Bardin (ed), B.C. Decker, Inc., Philadelphia, pp. 388-392, 1985.
35. Warner, B., Dufau, M., Santen, R. Effect of age and illness on LH bio/immuno ratio. IN: Hormone Action and Testicular Function, K.J. Catt and M. Dufau (ed), New York Academy of Science Publishers, New York, pp. 492-496, 1984.
36. Santen, R.J., English, H., Rohner, T., Drago, J., Lipton, A., Harvey, H., Simmonds, M., Boucher, A., Glode L.M., Wettlaufer, J., Gordon, R., Manni, A. Androgen depletion/repletion in combination with chemotherapy: Strategy for secondary treatment of metastatic prostatic cancer. IN: Progress in Clinical and Biological Research Volume 185A. EORTC Genitourinary Group Monograph No. 2: Therapeutic Principles in Metastatic Prostatic Cancer, F.H. Schroeder and B. Richards (ed), Alan R. Liss, Inc., New York, pp. 359-371, 1985.
37. Buchanan, J.R., Santen, R.J., Cavaliere, A., Cauffman, S.W., Greer, R.B., Demers, L.M. Physiological interaction between parathyroid hormone and estrogen. IN: Vitamin D: Chemical, Biochemical and Clinical Update, A.W. Norman, K. Schaefer, H.G. Grigoleit and D.V. Herrath (ed), DeGruyter, New York, p. 1095-1096, 1985.

38. Wells, S.A., Santen, R.J. The pituitary and adrenal glands. IN: Textbook of Surgery: The Biological Basis of Modern Surgical Practice, D.C. Sabiston (ed), W.B. Saunders Co., Philadelphia, pp. 639-696, 1986.
39. Kulin, H.E., Santen, R.J. Delayed adolescence. IN: Basic Clinical Endocrinology, P.O. Kohler (ed), J. Wiley and Sons, Inc., New York, pp. 343-358, 1986.
40. Brodie, A., Santen, R. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. IN: Critical Reviews in Oncology/Hematology Vol. 5, S. Davis (ed), CRC Press, Boca Raton, pp. 361-396, 1986.
41. Santen, R.J., Leszczynski, D., Tilson-Mallet, N., Feil, P.D., Wright, C., Manni, A., Santner, S.J. Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase vs. sulfatase pathways. IN: Endocrinology of the Breast: Basic and Clinical Aspects, Vol. 464, A. Angeli, H.L. Bradlow and L. Dogliotti (ed), New York Academy of Sciences Publishers, New York, pp. 126-137, 1986.
42. Santen, R.J., Kulin, H.E. Evaluation of delayed puberty and hypogonadism. IN: Male Reproductive Dysfunction: Diagnosis and Management of Hypogonadism, Infertility, and Impotence, R.J. Santen and R.S. Swerdloff (ed), Marcel Dekker, Inc., New York, pp. 145-189, 1986.
43. Manni, A., Santen, R.J. Clinical uses of aromatase inhibitors. IN: Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, F.J.A. Furr and A. Wakeling (ed), Praeger Scientific, East Sussex, pp. 271-287, 1986.
44. Manni, A., Santen, R.J., Boucher, A.E, Lipton, A., Harvey, H., Simmonds, M., White-Hershey, D., Gordon, R.A., Rohner, T.J., Drago, J., Wettlaufer, J., Glode, L.M. Androgen priming and response to chemotherapy in advanced prostate cancer. IN: EORTC Monograph Series: Intl. Symp. (Rotterdam) on Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents, J.G.M. Klijn, R. Paridaens and J.A. Foekens (ed), Raven Press, New York, pp. 517-522, 1986.
45. Santen, R.J. Current status of aromatase inhibitors for treatment of breast cancer: New perspectives. IN: EORTC Monograph Series: Intl. Symp. (Rotterdam) on Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents, J.G.M. Klijn, R. Paridaens and J.A. Foekens (ed), Raven Press, New York, pp. 71-80, 1986.
46. Santen, R.J. Determinants of tissue oestradiol levels in human breast cancer. IN: Cancer Surveys, Vol. 5: Hormones and Cancer: 90 Years after Beatson, R.D. Bulbrook (ed), Oxford University Press, London, pp. 597-616, 1986.
47. Santen, R.J. Disorders of the testis. IN: Internal Medicine, 2nd ed., J.H. Stein (ed), Little, Brown and Co., Boston, pp. 1979-1994, 1986.
48. Santen, R.J., Langecker, P., Santner, S.J. Sources of estrogen and aromatase inhibitors in breast cancer. IN: Proc. Third Intl. Cong. on Hormones and Cancer: Progress in Cancer Research and Therapy, Vol. 35: Hormones and Cancer 3, F. Bresciani, R.J.B. King, M.E. Lippman and J.P. Raynaud (ed), Raven Press, New York, pp. 326-333, 1987.

49. Veldhuis, J.D., Clifton, D.K., Crowley, Jr., W.F., Filicori, M., Johnson, M.L., Maciel, R.J., Merriam, G.R., Santoro, N.F., Steiner, R.A., Santen, R.J. Preferred attributes or objective pulse analysis methods. IN: The Episodic Secretion of Hormones, W.F. Crowley and J.G. Hofler (ed), John Wiley and Sons, Inc., New York, pp. 111-117, 1987
50. Santen, R.J., Bourguignon, J.P. Gonadotropin releasing hormone: Physiological and therapeutic aspects, agonists and antagonists. IN: Hormone Research: Recent Advances in the Pharmacologic Control of Gonadal Function, A. Caufriez and M.G. Forest (ed), S. Karger AG, Basel; Hormone Res. 28:88-103, 1987.
51. Santen, R.J. The testis. IN: Endocrinology and Metabolism, J. Baxter, A. Broadus and L. Frohman (ed), McGraw-Hill Book Co., pp. 821-982, 1987.
52. Santen, R.J. Perspectives for the clinical use of aromatase inhibitors. IN: Breast Cancer: Scientific and Clinical Progress, M.A. Rich, J.C. Hager and D.M. Lopez (ed), Kluwer Academic Publishers, Boston, pp. 285-298, 1988.
53. Potter, D.M., Santen, R.J. Adrenocortical insufficiency. IN: Conn's Current Therapy, R.E. Rekel (ed), W.B. Saunders Co., Philadelphia, pp. 523-525, 1988.
54. Manni, A., Santen, R.J. Clinical use of aromatase inhibitors in the treatment of breast cancer. IN: Endocrine Related Tumors II: Endocrine Therapies in Breast and Prostate Cancer, W.L. McGuire (ed), Kluwer Academic Publisher, pp. 67-82, 1988.
55. Manni, A., Santen, R.J., Boucher, A.E., Lipton, A., Harvey, H.A., Simmonds, M.A., White-Hershey, D., Gordon, R.A., Rohner, T.J., Wettlaufer, J., Glode, L.M. Androgen priming and chemotherapy in the treatment of advanced prostate cancer. IN: Acta Medica, 1st Intl. Symp. on Advances in Urologic Oncology, Sanremo, Italy, pp. 235-240, 1988.
56. Santen, R.J. Local estrogen production by human breast tumors. IN: Endocrine-Dependent Breast Cancer: Critical Assessment of Recent Advances, R.J. Santen and E. Juhos (ed), Hans Huber Publishers, Bern, pp. 49-57, 1988.
57. Manni, A., Santen, R.J., Boucher, A.E., Lipton, A., Harvey, H.A., Simmonds, M.A., White-Hershey, D., Gordon, R.A., Rohner, T.J., Drago, J., Wettlaufer, J., Glode, L.M. Androgen priming and chemotherapy in the treatment of advanced prostate cancer. IN: Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects, M. Motta and M. Serio (ed), Medicom (UK) Ltd., The Netherlands, pp. 361-369, 1988.
58. Santen, R.J. Hormonal treatment of prostate cancer. IN: Current Therapy in Endocrinology and Metabolism - 3, C.W. Bardin (ed), B.C. Decker, Inc., Philadelphia, pp. 404-410, 1988.
59. Santen, R.J., English, H.F. Biologic principles underlying treatment strategies for prostate carcinoma. IN: Serono Symposia Series, Vol. 53: Proc. IVth Intl. Cong. of Andrology, Florence, Italy, Raven Press, New York, pp. 449-457, 1989.
60. Santen, R.J. Disorders of the testis. IN: Internal Medicine, 3rd ed., J.H. Stein (ed), Little, Brown and Co., Boston, chapter 339, pp. 2222-2237, 1990.
61. Santen, R.J. Endocrine aspects of prostate cancer. IN: Principles and Practice of Endocrinology and Metabolism. K.L. Becker (ed), J.B. Lippincott Co., Philadelphia, pp. 1656-1663, 1990.

62. Manni, A., Santen, R.J., Boucher, A.E., Lipton, A., Harvey, H.A., Simmonds, M.A., White-Hershey, D., Bartholomew, M., Caplan, R., Gordon, R., Rohner, T.J., Drago, J., Wettlaufer, L.M. Novel approaches to the treatment of advanced prostate cancer. IN: Benign and Malignant Tumours, Vol. 3, B.H. Vickery and B. Lunenfeld (ed), Kluwer Academic Publishers, Boston, pp. 67-77, 1990.
63. Santen, R.J. Recent advances in the endocrine therapy of breast cancer. IN: Intl. Cong. Series 945: Cancer Chemotherapy Challenges for the Future, K. Kimura, K. Yamada, S.K. Carter and D.P. Griswold, Jr. (ed), Excerpta Medica 5:229-241, 1990.
64. Santen, R.J., Aromatase inhibitors: 1. IN: The Medical Management of Breast Cancer, T. Powles and I. Smith (ed), Martin Dunitz, pp. 61-79, 1991.
65. Santen, R.J. The principles of aromatase inhibition in the treatment of breast cancer. IN: Aromatase Inhibition: Present and Future, W. Jonat and R.J. Santen (ed), The Parthenon Publishing Group, Park Ridge, pp. 11-28, 1991.
66. Santen, R.J. Male hypogonadism. IN: Reproductive Endocrinology, 3rd ed., S.S.C. Yen and R.B. Jaffe (ed), W.B. Saunders Co., Philadelphia, pp. 739-794, 1991.
67. Harvey, H.A., Lipton, A., Santen, R.J., Demers, L., Henderson, I.C., Garber, J.E., Miller, A.A., Navari, R., Mulagha, M., Hanagan, J. Clinical trials with the aromatase inhibitor CGS 16949-A in advanced breast cancer. IN: Aromatase Inhibition: Present and Future, W. Jonat and R.J. Santen (ed), The Parthenon Publishing Group, Park Ridge, pp. 89-97, 1991.
68. Santen, R.J., Manni, A., English, H.F. Cell kinetics and hormone priming to potentiate chemotherapy. IN: Biological Modulators and Clinical Response in Oncology, A. Manni, F. Pannuta and G. Robustelli della Cuna (ed), Edizioni Medico-Scientifiche, Pavia, Italy, pp. 325-336, 1991.
69. Santen, R.J. Clinical use of aromatase inhibitors in breast carcinoma. IN: Cancer Medicine, 3rd ed., J.F. Holland, E. Frei, R.C. Bast, D.W. Kufe, D.L. Morton and R.R. Weichselbaum (ed), pp. 865-877, 1993.
70. Manni, A., Santen, R.J., Harvey, H.A. Endocrine treatment of breast cancer: Update 1993. Endocrine Reviews (Monograph) 1:46-48, 1993.
71. Santen, R.J. Gynecomastia. IN: Textbook of Endocrinology, Vol. 3, 3rd ed., L. DeGroot (ed), W.B. Saunders, Philadelphia, chapter 39, pp. 2474-2484, 1993.
72. Santen, R.J. Disorders of the testis. IN: Internal Medicine, 4th ed., J.H. Stein (ed), Mosby Publishers, St. Louis, pp. 1378-1388, 1994.
73. Santen, R.J. Solving the puzzle of hormone-dependent breast cancer. IN: Clinical Use of Aromatase Inhibitors: Current Data and Future Perspectives, B. Robustelli della Cuna, A. Manni and F. Pannuti (ed), Adv. Clin. Oncol. 2:27-34, 1994.
74. Santen, R.J. The testis. IN: Endocrinology and Metabolism, 3rd ed., P. Felig, J. Baxter, A. Broadus and L. Frohman (ed), McGraw-Hill Book Co., chapter 16, pp. 885-972, 1995.

75. Santen, R.J. Treatment of menopausal symptoms in women in whom estrogen is not acceptable or is contraindicated, UpToDate in Nephrology and Hypertension, Endocrinology and Diabetes, Cardiovascular Medicine, Pulmonary Disease and Critical Care, Burton Rose ed., Vol 5, No. 2, UpToDate, Inc., 1997.
76. Santen, R.J. Treatment of benign breast disease, UpToDate in Nephrology and Hypertension, Endocrinology and Diabetes, Cardiovascular Medicine, Pulmonary Disease and Critical Care, Burton Rose ed., Vol 5, No. 2, UpToDate, Inc., 1997.
77. Santen, R.J. Disorders of the testis. IN: Internal Medicine, 5th ed., J.H. Stein (ed), Mosby Publishers, St. Louis, pp 1838-1846, 1998.
78. Santen, R.J. Benign breast disease. IN: Internal Medicine, 5th ed., J.H. Stein (ed), Mosby Publishers, St. Louis, pp 1846-1850, 1998.
79. Bernstein, L.M., Pauley, R.J., Yue, W., Santen, R.J. Aromatase activity and transcripts in breast cancer tissue in relation to the effect of aromatase inhibitors in vitro. IN: 10th International Congress on Breast Diseases, J.C. da Silva (ed), Monduzzi Editore, Bologna, Italy, pp. 595-597, 1998.
80. Tekmal, R.R., Santen, R.J. Local estrogen production: is aromatase an oncogene. IN: Contemporary Endocrinology: Endocrinology of Breast Cancer, A. Manni (ed), Humana Press Inc., Totowa, NJ, pp.79-92, 1998.
81. Santen, R.J. The testis: function and dysfunction. IN: Reproductive Endocrinology, 4th ed., S.S.C. Yen and R.B. Jaffe (ed), W.B. Saunders Co., Philadelphia, pp. 632-668, 1999.
82. Santen, R.J. and Pinkerton, J.V. The Treatment of Estrogen Deficiency in Women at Risk for Breast Cancer and Survivors of the Disease IN: Sex Hormone Replacement Therapy. Henry Burger (ed), Kluwer Academic Publishers, Norwell, Massachusetts, pp. 43-81, 2000.
83. Russo, J., Santen, R.J., Russo, IH. Hormonal Control of Breast Development. IN: Textbook of Endocrinology, Vol. 2, 4th edition, L. DeGroot (ed), W.B. Saunders, Philadelphia, pp. 2181-2188, 2001.
84. Santen, R.J. and Pinkerton, J.V. Benign breast disorders. IN: Textbook of Endocrinology, Vol.3, 4th edition, L. DeGroot (ed), W.B. Saunders, Philadelphia, pp. 2189-2198, 2001.
85. Santen, R.J. Gynecomastia. IN: Textbook of Endocrinology, Vol. 3, 4th edition, L. DeGroot (ed), W.B. Saunders, Philadelphia, pp. 2335-2343, 2001.
86. Santen, R.J., Cerilli, L., and Harvey, J. Breast IN Comprehensive Clinical Endocrinology, 3rd edition, Michael Besser and Michael Thorner (eds), Harcourt Publishers Limited, London, pp 585-612, 2001.
87. Santen, R.J. Endocrine-Responsive Cancer IN: Williams Textbook of Endocrinology, 10th edition, Larsen, R., Kronenberg, H., Melmed, S., and Polonsky, K. (ed) W.B. Saunders Company, Philadelphia, PA, pp 1797-1833, 2002.

88. Yue, W., More, G., Naftolin, F., Pauley, R., Shim, W-S., Harvey, H., and Santen, R.J. Use of aromatase inhibitors in breast cancer. IN: Endocrine Therapy of Breast Cancer. John Roberson, Robert Nicholson, and Daniel Hayes (eds), Taylor and Francis Group, London, UK, pp. 75-106, 2002.
89. Pinkerton, J.V. and Santen, R.J. Use of alternatives to estrogen for treatment of menopause in survivors of breast cancer. IN: Menopause: The State of the Art in research and management, Schneider, H.P.C. (ed), The Parthenon Publishing Group, New York, pp. 378-401, 2003.
90. Santen, R.J. and Pinkerton, J.V. Use of alternatives to estrogen treatment of menopause IN Selective Estrogen Receptor Modulators: Research and Clinical Applications, Andrea Manni and Michael Verderame (eds), Humana Press, Totowa, New Jersey, pp313-343, 2002.
91. Santen RJ, Yue W, Bocchinfuso W, Korach K, Wang J-P, Rogan E, Li Y, Cavalieri E, Russo J, Devanesan P, and Verderame M. Estradiol-induced carcinogenesis via formation of genotoxic metabolites, IN: Advances in Endocrine Therapy of Breast Cancer: Proceedings of the 2003 Gleneagles Conference, Ingle, J.N. and Dowsett, M. (eds), Marcel Dekker, New York, NY, pp. 13-177, 2004.
92. Santen, R.J. Endocrinology of Breast and Endometrial Cancer IN: Yen and Jaffe's Reproductive Endocrinology, 5th ed., Jerome F. Strauss III and Robert L. Barbieri, Elsevier, Philadelphia, PA. 2004, pp. 787-809.
93. Russo, J., Santen, R.J. and Russo, I.H. Hormonal Control of Breast Development. IN: Endocrinology, 5th Edition, DeGroot, L.J. and Jameson, J.L., eds., Elsevier Saunders, Philadelphia, PA, 2006, pp. 3045-3056.
94. Santen, R.J. Benign Breast Disorders. IN: Endocrinology, 5th Edition, DeGroot, L.J. and Jameson, J.L., eds. Elsevier Saunders, Philadelphia, PA, 2006, pp. 3057-3072.
95. Santen, R.J. Gynecomastia. IN: Endocrinology, 5th Edition, DeGroot, L.J. and Jameson, J.L., eds. Elsevier Saunders, Philadelphia, PA, 2006, pp. 3283-3294.
96. Pinkerton, J.V. and Santen, R.J. Alternatives to hormone therapy in menopausal women. IN: Climacteric Medicine chapter 39. 1st proof 6/23/04
97. Howell, A., Clarke, R.B., Evans, G., Bundred, N., Cuzick, J., Santen, R., and Allred, C. Estrogen deprivation for breast cancer prevention in Recent Results in Cancer Research, Vol. 174, pp 153-169.
98. Santen, R.J. Breast Cancer. IN: Yen and Jaffe's Reproductive Endocrinology, 6th Edition, Strauss III, J. E. and Barbieri, R.L., eds. Elsevier Saunders, Philadelphia, PA, 2009, pp.659-686.
99. Santen, R.J. Benign breast disease in women. Endotext.org (electronic textbook of Endocrinology), DeGroot, L., ed., 2010.
100. Russo, J., Santen, R.J., Russo, I.H. Hormonal control of breast development. IN: Endocrinology, vol. II, 6th edition. Jameson, J.L., DeGroot, L.J., eds. Elsevier Saunders, Philadelphia, PA, 2010, pp. 2265-2273.
101. Santen, R.J., Gynecomastia. IN: Endocrinology, vol. II, 6th edition. Jameson, J.L., DeGroot, L.J., eds. Elsevier Saunders, Philadelphia, PA, 2010, pp. 2544-2555.

102. Santen, R.J. The breast: lactation and breast cancer as an endocrine disease. In: Oxford Textbook of Endocrinology and Diabetes, 2nd edition. Wass, J.A.H., Stewart, P.M., eds. Oxford University Press, 2011, pp. 1305-1318.
103. Santen, R.J., Yager, J.D. Role of estrogens in the development of breast cancer. In: World Breast Cancer Report, 2012. Boyle, P., Autier, P., Adebamowo, C., Anderson B., Pinillos Aston, L, Badwe, R.A., Yamaguchi, N., eds. International Prevention Research Institute, 2012, pp. 197-212.
104. Santen, R.J., Duska, L.R., Culp, S.H. Hormone responsive cancers. In: Yen & Jaffe's Reproductive Endocrinology. Physiology, Pathophysiology, and Clinical Management, 7th edition. Strauss, J.F., Barbieri, R.L., eds. Elsevier, 2014, pp. 651-698.

Book Editor

1. Santen, R.J., Lipton, A., Harvey, H., Wells, S.A. Use of aminoglutethimide and hydrocortisone as a “medical adrenalectomy” for treatment of breast cancer. IN: Progress in Cancer Research, I.M. Ariel (ed), Grune and Stratton, Inc., New York, pp. 245-265, 1982.
2. Santen, R.J., Manni, A. Controversies in the treatment of endocrine tumors: Medical and surgical management of prolactinomas and thyroid cancer. IN: Diagnosis and Management of Endocrine-Related Tumors, R.J. Santen and A. Manni (ed), Martinus-Nijhoff Publishers, The Hague, pp. 419-437, 1984.
3. Santen, R.J. and Juhas, E. (ed). Endocrine-Dependent Breast Cancer: Critical Assessment of Recent Advances, Hans Huber Publishers, Bern, 1988.
4. Jonat, W., Santen, R.J. (ed). Aromatase Inhibition: Present and Future, The Parthenon Publishing Group, Park Ridge, 1991.
5. Miller, W.R. and Santen, R.J. (eds) Aromatase Inhibition and Breast Cancer. Marcel Dekker Inc. New York, 2000.
6. Berstein LM, Santen RJ. (ed) Innovative Endocrinology of Cancer Advances in Experimental Medicine and Biology Series # 630. Springer Science and Business Media , LLC, Landes Bioscience Publishers . 2008, New york, New York

Peer-Reviewed Patient Education Documents

Santen, R.J., Borwhat, M., Gleason, S. Menopause: treatment options for women surviving breast cancer or concerned about estrogen replacement therapy. The Hormone Foundation. 1998.

Non-Peer-Reviewed Patient Education Documents

Santen, R.J. Causes and treatment for breast pain. The Breast Health Communique: A Newsletter for Certified Instructors, 6:2, 1999.

Haden, K. and Santen, R.J. Breast cancer prevention with tamoxifen. Primary Care Practice (In press 2000)

Santen, R.J. Gynecomastia. Clinical Endocrinology Update '96 Syllabus, pp. 107-115, 1996.

Santen, R.J. Treatment strategies for testicular dependent disorders. Syllabus Clinical Endocrinology Update, pp. 65-73, 1996.

Simon, J.A., Archer, D.F., Santen, R.J., Utian, W.H., Wysocki, S. The evolving use of estrogen and hormone therapy. Practical advice for the practicing clinician. Available at obgmanagement.com, November 2011.

Letter to the Editor

Santen, R.J. Letter to the editor: McCune-Albright syndrome. Growth Genetics & Hormones 14:42, 1998.

Santen, R.J., Burger, H.G. Letter to the editor: Update in hormone therapy use in menopause. Journal of Clinical Endocrinology and Metabolism. Published online March 30, 2011 (<http://jcem.endojournals.org/letters>).

Presented Abstracts

List provided upon request.